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A B S T R A C T
Background
Agitation has been reported in up to 90% of people with dementia. Agitation in people with dementia worsens carer burden, increases
the risk of injury, and adds to the need for institutionalisation. Valproate preparations have been used in an attempt to control agitation
in dementia, but their safety and efficacy have been questioned.
Objectives
To determine the efficacy and adverse effects of valproate preparations used to treat agitation in people with dementia, including the
impact on carers.
Search methods
We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 7 December 2017 using
the terms: valproic OR valproate OR divalproex. ALOIS contains records from all major health care databases (the Cochrane Library,
MEDLINE, Embase, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources.
Selection criteria
Randomised, placebo-controlled trials that assessed valproate preparations for agitation in people with dementia.
Data collection and analysis
Two review authors independently screened the retrieved studies against the inclusion criteria and extracted data and assessed method-
ological quality of the included studies. If necessary, we contacted trial authors to ask for additional data, including relevant subscales, or
for other missing information. We pooled data in meta-analyses where possible. This is an update of a Cochrane Review last published
in 2009. We found no new studies for inclusion.
Main results
The review included five studies with 430 participants. Studies varied in the preparations of valproate, mean doses (480 mg/day to 1000
mg/day), duration of treatment (three weeks to six weeks), and outcome measures used. The studies were generally well conducted
although some methodological information was missing and one study was at high risk of attrition bias.
The quality of evidence related to our primary efficacy outcome of agitation varied from moderate to very low. We found moderate-
quality evidence from two studies that measured behaviour with the total Brief Psychiatric Rating Scale (BPRS) score (range 0 to 108)
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and with the BPRS agitation factor (range 0 to 18). They found that there was probably little or no effect of valproate treatment over
six weeks (total BPRS: mean difference (MD) 0.23, 95% confidence interval (CI) -2.14 to 2.59; 202 participants, 2 studies; BPRS
agitation factor: MD -0.67, 95% CI -1.49 to 0.15; 202 participants, 2 studies). Very low-quality evidence from three studies which
measured agitation with the Cohen-Mansfield Agitation Index (CMAI) were consistent with a lack of effect of valproate treatment on
agitation. There was variable quality evidence on other behaviour outcomes reported in single studies of no difference between groups
or a benefit for the placebo group.
Three studies, which measured cognitive function using the Mini-Mental State Examination (MMSE), found little or no effect of
valproate over six weeks, but we were uncertain about this result because the quality of the evidence was very low. Two studies that
assessed functional ability using the Physical Self-Maintenance Scale (PSMS) (range 6 to 30) found that there was probably slightly
worse function in the valproate-treated group, which was of uncertain clinical importance (MD 1.19, 95% CI 0.40 to 1.98; 203
participants, 2 studies; moderate-quality evidence).
Analysis of adverse effects and serious adverse events (SAE) indicated a higher incidence in valproate-treated participants. A meta-
analysis of three studies showed that there may have been a higher rate of adverse effects among valproate-treated participants than
among controls (odds ratio (OR) 2.02, 95% CI 1.30 to 3.14; 381 participants, 3 studies, low-quality evidence). Pooled analysis of the
number of SAE for the two studies that reported such data indicated that participants treated with valproate preparations were more
likely to experience SAEs (OR 4.77, 95% CI 1.00 to 22.74; 228 participants, 2 studies), but the very low quality of the data made it
difficult to draw any firm conclusions regarding SAEs. Individual adverse events that were more frequent in the valproate-treated group
included sedation, gastrointestinal symptoms (nausea, vomiting, and diarrhoea), and urinary tract infections.
Authors’ conclusions
This updated review corroborates earlier findings that valproate preparations are probably ineffective in treating agitation in people with
dementia, but are associated with a higher rate of adverse effects, and possibly of SAEs. On the basis of this evidence, valproate therapy
cannot be recommended for management of agitation in dementia. Further research may not be justified, particularly in light of the
increased risk of adverse effects in this often frail group of people. Research would be better focused on effective non-pharmacological
interventions for this patient group, or, for those situations where medication may be needed, further investigation of how to use other
medications as effectively and safely as possible.
P L A I N L A N G U A G E S U M M A R Y
Valproate preparations for the treatment of agitated behaviour in people with dementia
Background
Agitated behaviour is very common in the later stages of dementia. It can include verbal behaviours, such as shouting, and physical
behaviours, such as wandering or physical aggression. It has been shown to worsen the stress experienced by family carers, increase the
risk of injury, and increase the need for people with dementia to move into institutional care.
A type of medication that has been used to treat agitated behaviour in people who have dementia is valproate, which is available in
several different preparations (valproic acid, divalproex sodium, sodium valproate, and valproate semi-sodium). These medications are
not recommended in current guidelines (e.g. from the National Institute for Health and Care Excellence), but are sometimes still given
to people with dementia to treat agitated behaviour.
Purpose of this review
We wanted to review the evidence about how effective and safe it is to give valproate preparations to people with dementia to treat
agitation.
Studies included in this review
We searched medical databases up to December 2017 for studies that compared any preparation of valproate with a placebo (dummy
tablet) to treat agitated behaviour in people diagnosed with dementia.
We included five studies with 479 participants who had various types of dementia and agitated behaviour. Most studies lasted for six
weeks, although one was only three weeks long. The studies were generally well conducted, but the methods were not always fully
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reported and one study was at high risk of bias because of the high number of people who dropped out from the valproate-treated
group.
Key findings
Studies measured agitated behaviour with various scales and the reliability of the evidence for the different scales ranged from moderate
to very low. Overall, we found no evidence that valproate preparations improved behaviour, or specifically, agitated behaviour. We
found that valproate preparations probably had little or no effect on participants’ ability to perform daily activities. We could not be
sure whether they had an effect on cognition (thinking and remembering) because the reliability of the evidence was very low.
We found low-reliability evidence from three studies that participants taking valproate may be more likely than those taking placebo
to experience harmful effects. We could not be as certain about differences in serious harms, such as serious illness or admission to
hospital, but data from two studies suggested that these may be more common in the participants taking valproate. Some of the side
effects associated with valproate were sleepiness, feeling sick, being sick, watery stools, and urinary tract infections.
Conclusions
We only identified five relatively small studies for inclusion in this review. They varied in their methods, type of medicine and its dose,
duration of treatment, and scales used to make measurements. This limited our ability to pool data across studies. However, we could
be moderately confident in the conclusion that valproate preparations do not improve agitated behaviour in dementia. They may also
be associated with harmful effects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Valproate preparations compared to placebo for agitation in dementia
Patient or population: people with agitat ion in dementia
Setting:
Intervention: valproate preparat ions
Comparison: placebo
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GRADE Working Group grades of evidence
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B A C K G R O U N D
Description of the condition
Agitation is reported in up to 90% of people with dementia
(Alzheimer’s Society 2011a). A widely accepted definition of ag-
itation is: “inappropriate verbal, vocal, or motor activity that
is not explained by needs or confusion per se” (Billig 1991;
Cohen-Mansfield 1989). The descriptors of agitation include
wandering, crying out, aggressiveness, repetitive movements, and
unco-operative behaviour. Agitation in people with dementia
worsens carer burden, increases the risk of injury, and adds to the
need for institutionalisations (Livingstone 2014).
Description of the intervention
Current guidelines recommend that people with dementia who
develop non-cognitive symptoms or behaviours that cause them
distress or challenge those who provide their care should first have
a comprehensive assessment to determine likely causative factors,
such as physical illness, depression, pain, adverse effects of medi-
cation, personal or psychosocial factors, or aspects of their phys-
ical environment. Appropriate steps should then be taken to ad-
dress those factors, and a period of ’watchful waiting’ should be
observed, if possible, as in many cases symptoms will improve or
resolve over four to six weeks (Alzheimer’s Society 2011a). The
guidelines also suggest that consideration should be given to pro-
viding individualised interventions such as aromatherapy or mul-
tisensory stimulation as there is some evidence of their clinical
effectiveness (Livingstone 2014; NICE 2006). In fact, research
has shown that just 10 minutes of one-to-one time each day can
reduce behavioural and psychological symptoms associated with
dementia (BPSD) (Alzheimer’s Society 2011b).
The National Institute for Health and Care Excellence (NICE)
guideline on supporting people with dementia and their carers sug-
gests that people with dementia who present with non-cognitive
symptoms or challenging behaviour should be offered pharmaco-
logical intervention in the first instance “only if they are severely
distressed or there is an immediate risk of harm to the person or
others” and that a thorough assessment of possible causes of the
behaviour should be carried out as soon as possible (NICE 2016).
Drug treatment for the control of violence, aggression, and ex-
treme agitation should be implemented with the aim of avoiding
sedation and the use of high doses or combinations of drugs, and
with careful monitoring of the person’s physical condition and any
adverse effects (NICE 2006).
If drug treatment of agitation is considered necessary, then the drug
classes recommended by NICE, in order, are antipsychotics, acetyl-
cholinesterase inhibitors, and memantine. There is some evidence
of modest benefits of antipsychotics in around 50% of people with
dementia, but they are associated with adverse effects such as se-
dation, parkinsonism, gait disturbance, dehydration, falls, chest
infection, accelerated cognitive decline, and stroke, and they are
associated with increased mortality in the long term (Alzheimer’s
Society 2011b; Maher 2011). The increased risk of cerebrovascu-
lar adverse events and death in this patient group resulted in a
Medicines and Healthcare products Regulatory Agency (MHRA)
warning that no antipsychotic should be used for this indication
in dementia (except risperidone in some circumstances) (MHRA
2012). Risperidone is the only antipsychotic licensed for people
with dementia, and guidelines recommend treatment should be
used for no longer than 12 weeks. The evidence of benefit of other
types of antipsychotics is more limited, and use for BPSD is off-
label. Acetylcholinesterase inhibitors and memantine are licensed
for the treatment of cognitive symptoms in Alzheimer’s disease
and there is some evidence that these medications may positively
impact on agitated behaviour, although there is no evidence that
they specifically improve agitation ( NICE 2006).
Other medications that have been used to treat agitated behaviour
in people with dementia include benzodiazepines, hypnotics, an-
tidepressants, and anticonvulsants. There is no evidence of benefit
of benzodiazepines for this indication, and they carry increased
risk of adverse effects (Bierman 2007). There is relatively little evi-
dence relating to antidepressants for agitated behaviour in demen-
tia; findings on efficacy are mixed and there is evidence of adverse
effects (Porteinsson 2014; Seitz 2011). Among anticonvulsants,
carbamazepine and valproate preparations have both been used
widely.
How the intervention might work
Various valproate preparations are available: valproic acid, dival-
proex, sodium valproate, and valproate semi-sodium. Suggested
mechanisms by which valproic acid may have an impact on ag-
itation include enhancement of the intracerebral neurotransmit-
ting agent, gamma-butyric acid (GABA), antimanic action, and
mood stabilising effect (Lon 1995). Since 1996, a more readily
tolerated compound of valproate, divalproex, has been used. This
drug differs slightly from valproic acid in that peak blood flow
levels occur later (three to six hours, compared with three hours),
but the dosage and half-life of this drug are identical to those of
valproic acid. Sodium valproate is licensed for the treatment of
epilepsy in standard-release oral preparations, and in modified-re-
leased preparations for various indications according to the prepa-
ration. Sodium valproate or valproate semi-sodium is licensed for
the treatment of manic episodes in bipolar disorder. None of the
valproate preparations are licensed for the management of agitated
behaviour in people with dementia; therefore, use of for this pur-
pose is off-label.
Adverse effects associated with valproate preparations include falls,
gait disturbances, sedation, tremor, muscular weakness, depressed
mood, gastrointestinal disorders ( nausea, vomiting, constipation,
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and diarrhoea), urinary tract infections ( UTI), and thrombocy-
topenia. The current NICE advice on the use of valproate prepara-
tions for the management of aggression, agitation, and behavioural
disturbances in dementia states that current evidence suggests that
such medications are no more effective than placebo, and that ad-
verse effects are also more common in people taking them ( NICE
2015).
Why it is important to do this review
This is an update of a Cochrane Review first published in 2004,
and previously updated in 2009.
One summary of evidence published by NICE suggests that val-
proate preparations are no more effective than placebo for agita-
tion in dementia ( NICE 2015). Despite this guidance, valproate
preparations are still sometimes being used in this patient group,
perhaps because other drug options are not always effective and
may be associated with adverse effects. This update is intended to
apply current Cochrane methods to synthesise the evidence con-
cerning use of valproate for agitation in dementia, and to assess
the quality of this evidence, in order to inform decision-making
by carers, clinicians, researchers, and policy-makers.
O B J E C T I V E S
To determine the efficacy and adverse effects of valproate prepa-
rations used to treat agitation in people with dementia, including
the impact on carers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised, placebo-controlled trials. We ex-
cluded interrupted time series trials. Where studies used a cross-
over design, we included only data from the first part of the study.
Types of participants
We included participants of either sex and of any age, both inpa-
tients and outpatients (with or without carers). Dementia should
have been diagnosed according to the classifications provided by
Diagnostic and Statistical Manual of Mental Disorders, 4th edi-
tion (DSM-IV) (APA 1994), International Classification of Dis-
eases, 10th edition (ICD-10) (WHO 1991), Diagnostic and Sta-
tistical Manual of Mental Disorders, 3rd edition (DSM-III) (APA
1980), or Diagnostic and Statistical Manual of Mental Disorders,
3rd revised edition (DSM-IIIR) (APA 1987). In the absence of
these criteria, we also accepted other evidence of dementia such
as the Mini-Mental State Examination (MMSE) (Folstein 1975),
psychiatric evaluation, psychological evaluation, or a medical eval-
uation. We accepted definitions of agitation provided by individ-
ual investigators.
Because agitation is common in delirium, we had initially spec-
ified that all studies should have included clinical evaluation to
rule out delirium and other treatable causes of agitation (e.g. pain,
infection, drug effect, urinary or faecal retention) prior to enter-
ing people into the trial. However, reporting of baseline clinical
evaluation was not always specific or detailed. Therefore, we took
a pragmatic approach to avoid risking the loss of relevant evidence
and included studies despite this information not being explicitly
reported.
Types of interventions
We required at least one week of treatment with valproate prepa-
rations, of any dosage given by mouth, compared with placebo.
People receiving stable therapy with other psychoactive medica-
tions, including cholinesterase inhibitors, memantine, and antide-
pressants, could be included if this was permitted in the study
protocol.
Types of outcome measures
Primary outcomes
• Agitation, or one or more aspects of agitation as measured
by a scale that specifically measured agitation, either exclusively
or as one of its components. The scales included but were not
limited to:
◦ Cohen-Mansfield Agitation Inventory (CMAI;
Cohen-Mansfield 1986);
◦ Social Dysfunction and Agitation Scale (SDAS;
Wistedt 1990);
◦ Clinical Global Impression Scale for Aggression (CGI;
Guy 1976);
◦ “Nurse Observation” scale (Colenda 1991);
◦ Behavior Observation Scale of Intramural
Psychogeriatric Patients (GIP; Verstraten 1988);
◦ Brief Psychiatric Rating Scale (BPRS; Overall 1962;
Overall 1988);




• Overall clinical impression.
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• Effect on carers (carers’ psychological morbidity or burden).
• Incidence and severity of adverse effects.
• Dropouts, including dropouts due to adverse events.
Search methods for identification of studies
Electronic searches
We searched ALOIS ( www.medicine.ox.ac.uk/alois), which is the
Cochrane Dementia and Cognitive Improvement Group’s (CD-
CIG) Specialized Register on 2 October 2014. The search terms
used were: valproic OR valproate OR divalproex.
The Information Specialists for the CDCIG maintain ALOIS,
which contains studies that fall within the areas of dementia pre-
vention, dementia treatment and management, and cognitive en-
hancement in healthy older populations. The studies are identified
through:
• monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsycINFO, and
Lilacs;
• monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the World Health Organization
(WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the
Chinese Clinical Trials Register; the German Clinical Trials
Register; the Iranian Registry of Clinical Trials and the
Netherlands National Trials Register, plus others);
• quarterly searches of the Central Register of Controlled
Trials (CENTRAL);
• six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to Theses
and Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website ( www.medicine.ox.ac.uk/alois).
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL, and conference
proceedings can be viewed in the ’methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Searching other resources
We performed additional searches in many of the sources listed
above to cover the timeframe from the last searches performed for
ALOIS to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
We carried out the most recent search for this review on 7 De-
cember 2017. Previous searches were done in October 2016, July
2010, and February 2008.
Data collection and analysis
Selection of studies
The Information Specialist of the CDCIG removed duplicates of
the same references. Two review authors (ETL and JL) indepen-
dently examined titles and abstracts against the prespecified in-
clusion criteria to exclude clearly ineligible studies. We examined
any potentially eligible trial in full text. Two review authors (ETL
and JL) independently evaluated full texts according to the eli-
gibility criteria. We compared selections of trials and the review
authors agreed the final list of studies. We explained final decisions
for the exclusion of articles that we retrieved in full text in the
Characteristics of excluded studies table.
Data extraction and management
Two review authors (ETL and JL) extracted data from each study
using a data collection form that was piloted by the team. For the
purpose of this updated review, the data were entered into Review
Manager 5 (Review Manager 2014). Two review authors (AC and
SFB) checked the data for accuracy. We also extracted data about
ongoing studies, including study name, methods, participants,
interventions, outcomes, starting date, contact information, and
notes.
Assessment of risk of bias in included studies
Two review authors (SFB and AC) independently assessed the risk
of bias in accordance with Cochrane’s tool for assessing method-
ological quality and risk of bias (Higgins 2011). This tool assesses
how the randomisation sequence was generated, how allocation
was concealed, the integrity of blinding (participants, raters, and
personnel), the completeness of outcome data, selective reporting,
and other biases. Where inadequate details of randomisation and
other characteristics of the trials were provided, we contacted au-
thors of the studies to obtain further information.
We described the risk of bias of all included studies in the
Characteristics of included studies table and narratively. In ad-
dition, we provided an overall judgement of included studies in
a ’Risk of bias’ summary (see Figure 1). Where the two review
authors disagreed on ’Risk of bias’ decisions, the final rating was
made by consensus discussion involving the third member of the
review team.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Measures of treatment effect
We used the mean difference (MD) to measure the treatment ef-
fect. If the same outcome was assessed using different scales, then
we used the standardised mean difference (SMD). We reported
95% confidence intervals (CI). We reported results of dichoto-
mous outcomes as odds ratios (OR) with 95% CI.
Unit of analysis issues
We considered only participant-level outcomes. We analysed
change in outcome measure from pre- to post-treatment. For cross-
over trials, we used data for the first period only (if available) be-
cause of the possibility of carry-over effects.
Dealing with missing data
To allow an intention-to-treat analysis, we sought data irrespective
of compliance, whether or not the participant was subsequently
deemed ineligible, or otherwise excluded from treatment or follow-
up. If intention-to-treat data were not available in the publications,
we extracted ’on-treatment’ data or the data of participants who
completed the trial and indicated it as such. We did not use data
from titration phases prior to the randomised phase to assess safety
or efficacy.
Assessment of heterogeneity
We considered clinical heterogeneity between trials (participants,
interventions, and outcomes) when deciding whether or not to
synthesise data. Where we performed a meta-analysis, we used a
standard Chi2 test to check for heterogeneity. We also assessed the
impact of heterogeneity on the meta-analysis using the I2 statistic.
Assessment of reporting biases
We tried to minimise the impact of publication bias by searching
for both published and unpublished trials. We compared confer-
ence abstracts and registered trials with published data. We con-
tacted the responsible organisation or the researcher for more in-
formation when we found studies in trial registries that appeared
to have been completed but not published (see Description of
studies). We found too few studies to allow assessment of possible
publication bias using funnel plots and Egger’s test for asymmetry
(Egger 1997).
Data synthesis
Where data were suitable for a meta-analysis, we presented the
effect estimate from a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
Due to the low number of included studies, subgroup analysis
was not possible. Therefore, participants were combined into the
category of ’dementia’ regardless of subtype.
Sensitivity analysis
We did not conduct any sensitivity analyses.
’Summary of findings’ table
We used the GRADE approach to assess the quality of the sup-
porting evidence behind each estimate of treatment effect. We
presented key outcomes in Summary of findings for the main
comparison, including, for each outcome, a summary of the
amount of data, the magnitude of the effect size, and the overall
quality of the evidence (Schünemann 2011). The measures in-
cluded were: change in agitation and aggression, cognition, func-
tional performance, and incidence and severity of adverse effects.
R E S U L T S
Description of studies
Results of the search
The initial search for eligible RCTs was completed in August
2005. This identified three studies for inclusion in the review
(Porsteinsson 2001; Sival 2002; Tariot 2001). An updated search
on 7 February 2008 retrieved two new studies (Herrmann 2007;
Tariot 2005). Further updated searches on 30 July 2010, and 4
November 2016 identified no new studies for either inclusion or
exclusion in the review. The most recent search was performed in
December 2017.
After removal of duplicates and first assessment by the Informa-
tion Specialist of the CDCIG based on a screening of titles and ab-
stracts, these searches resulted in a total of 41 records being passed
to the authors for further scrutiny.
See Figure 2 for the flow of studies for this review.
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Figure 2. Study flow diagram.
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Included studies
We identified five studies eligible for inclusion (Herrmann 2007;
Porsteinsson 2001; Sival 2002; Tariot 2001; Tariot 2005). A de-
tailed description of each study is given in the Characteristics of
included studies table.
Design
Two studies were placebo-controlled crossover studies (Herrmann
2007; Sival 2002). In Sival 2002, there were two three-week
treatment periods separated by a one-week washout period. In
Herrmann 2007, the treatment periods lasted six weeks and there
was a two-week washout period between treatments. The remain-
ing three studies were parallel-group, placebo-controlled RCTs
with six-week treatment periods (Porsteinsson 2001; Tariot 2001;
Tariot 2005).
Sample size
The two crossover studies were the smallest with 14 (Herrmann
2007) and 43 (Sival 2002) participants. Porsteinsson 2001 had 56
participants, Tariot 2001 had 173, and Tariot 2005 had 153.
Setting
One study was conducted in Europe (Sival 2002), and another in
Canada (Herrmann 2007). Three were multisite studies in the US
(Porsteinsson 2001; Tariot 2001; Tariot 2005). All studies involved
people who were institutionalised. In Sival 2002, the participants
were from a short-stay ward at a psychiatric hospital; in the other
studies, participants were resident in long-term care facilities.
Participants
See Table 1 for a description of the participants’ characteristics at
baseline in all studies.
All studies included participants with dementia, mostly with mod-
erate-to-severe dementia. All studies used one or more standard
methods to diagnose dementia, including Alzheimer’s disease, vas-
cular dementia, and mixed dementia (DSM-IV (APA 1994); Na-
tional Institute of Neurological and Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA; McKhann 1984)).
Sival 2002 used the Clinical Dementia Rating Scale (Hughes
1982), in which 2/42 participants were classified as “light,” 24/
42 participants as “moderate,” and 14/42 participants as “severe.”
This same study used the MMSE (Folstein 1975), but 14 partic-
ipants could not be scored because of low level of function. All
other studies also used the MMSE. Mean scores at baseline were
7.4 (Tariot 2001), 6.8 (Porsteinsson 2001), 4.5 (Herrmann 2007),
and 10.8 (range 4 to 24) (Tariot 2005).
Inclusion criteria relating to degree of agitated behaviour varied be-
tween studies, but all studies required included participants to ex-
hibit minimum levels of agitation according to standardised mea-
sures (Neuropsychiatric Inventory (NPI), BPRS, Social Dysfunc-
tion and Aggression Scale-9).
• Herrmann 2007 required participants to display “significant
BPSD” as indicated by a score of 8 or greater on the NPI.
• Porsteinsson 2001 required participants to have exhibited
agitated behaviour for a minimum of two weeks “with sufficient
intensity” to result in a BPRS score of three or more on items
relating to tension, hostility, unco-operativeness, or excitement.
• Sival 2002 used Patel’s criteria for aggressive behaviour
(Patel 1993), and also required participants to score 3 or greater
on at least one item of the Social Dysfunction and Aggression
Scale-9.
• Tariot 2001 included participants who exhibited “manic
symptoms” according to the Bech-Rafaelsen Mania Scale
(BRMS) and six items of the BPRS. Participants were required to
score 15 or greater on the BRMS and 3 or greater on two or
more of the items of the BPRS relating to tension, grandiosity,
hostility, suspiciousness, unco-operativeness, and excitement,
with a total score of 15 or more.
• Tariot 2005 required participants to have at least a two-
week history of agitation with a total score greater than 2 on the




One study treated participants with divalproex sodium delayed-
release tablets or placebo (Tariot 2001). Dosage started at 125 mg
twice daily and was titrated to 20 mg/kg/day to 30 mg/kg/day,
to be reduced if intolerable adverse effects appeared. The median
dose for treated participants at the end of six weeks was 1000 mg/
day. One study treated participants with rapid-acting divalproex
sodium at an initial dose of 375 mg/day which was titrated up-
wards to a mean dose of 826 mg/day (Porsteinsson 2001). In this
trial, a non-blinded supervising physician, who had no contact
with the blinded researchers, altered drug dosage by 125 mg/day,
depending on written reports by the researchers of response and
adverse effects. In Tariot 2005, participants commenced sprinkle
formulation divalproex sodium 125 mg twice daily for three days,
which was increased in 125 mg increments every three days to
750 mg/day or up to a maximum dose 1000 mg/day. Researchers
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decreased the dose by 125 mg/day if a participant experienced ad-
verse effects. The mean dose at the end of the treatment period
was 800 mg/day.
Sodium valproate
In Sival 2002, study participants received sodium valproate 240
mg twice daily for three weeks. Participants in Herrmann 2007
received valproate 125 mg liquid suspension twice daily, increased
to 500 mg twice daily over the first two weeks. The dose could
then be increased to a maximum of 1500 mg/day or decreased
based on efficacy and tolerability as determined by a blinded study
physician.
All studies permitted short-term use of short-acting psychotrop-
ics. Porsteinsson 2001 used chloral hydrate. Tariot 2001 permit-
ted short-term use of lorazepam, oxazepam, or chloral hydrate as
needed. Sival 2002 allowed oxazepam for severe anxiety or in-
somnia. Tariot 2005 permitted zolpidem or lorazepam (or both)
for severe agitation or sleep-induction. Herrmann 2007 permitted
loxapine as a rescue medication.
Outcomes
All included studies aimed to assess the effect of valproate treat-
ments on agitation, aggression, mania, and overall function of peo-
ple with dementia.
The instruments used to measure the outcomes in each study are
given in Table 2.
Agitation and aggression
The included studies used several different scales to assess change
in agitated and aggressive behaviour.
Four studies used the CMAI scale to measure agitation and
aggression (Herrmann 2007; Porsteinsson 2001; Tariot 2001;
Tariot 2005). It was not clear which version of the CMAI was
used, although three gave the same source reference for the scale
(Herrmann 2007; Porsteinsson 2001; Tariot 2005). Tariot 2005
stated that they used a 36-item version of CMAI, whereas the
most commonly used version is the 29-item version. Information
obtained from the author suggested that they actually used the 29-
item version of the scale. Herrmann 2007 and Porsteinsson 2001
did not state specifically which version of the CMAI they used in
their studies. We attempted to contact these authors to clarify the
scale version and scoring used. Tariot 2001 used a different ver-
sion of the scale specifically designed for nursing home residents
(Cohen-Mansfield 1989).
Three studies used the BPRS to assess disturbed behaviour
(Porsteinsson 2001; Tariot 2001; Tariot 2005), and two studies
also used the agitation and hostility subscales of the BPRS as out-
come measures (Porsteinsson 2001; Tariot 2005). All three stud-
ies used the 18-item scale but two studies rated items 0 to 6
(Tariot 2001; Tariot 2005), whereas one study rated items 1 to 7
(Porsteinsson 2001). While this would lead to disparity in total
scores in each study, analysis of change in score in each study were
still comparable. Information relating to the scoring of the agita-
tion and hostility subscales of the BPRS was not available from the
authors of the studies which used them, and could not be found
through a further literature search.
Tariot 2001 used the BRMS to assess manic symptoms.
Porsteinsson 2001 used the OAS to measure aggression. Herrmann
2007 used the NPI and its agitation subscale at their primary out-
come measure. Sival 2002 used the Social Dysfunction and Ag-
gression-9 Scale (SDAS-9), and the “Nurse Observation” scale, to
measure incidence of aggression; the CGI to rate clinical impres-
sion of aggressive behaviour; and GIP to measure other types of
disturbed behaviour.
• The CMAI examines 29 types of agitated behaviour,
including pacing, verbal or physical aggression, screaming, and
restlessness. The frequency of these behaviours is measured on a
29-item scale with each item rated from 0 (never occurs) to 6
(occurs several times an hour) and scores for physical and verbal
aggression and overall aggression may be aggregated.
• The BPRS measures physical and verbal aggression,
hallucinatory behaviour, and abnormal thought content. The
scale comprises 18 items each scored on a 7-point scale with a
higher score indicating higher level of dysfunction.
• The CGI uses a 7-point scale with scores ranging from 1
(no aggressive behaviour) to 7 (severely aggressive behaviour). It
is also used to measure overall response to treatment.
• The BRMS is an 11-item observer-based scale that rates the
severity of manic symptoms on a 5-point scale (Bech 1978).
• The OAS quantifies aggressive verbal and physical
behaviours and includes the number, specific nature, and
intervention response.
• The NPI is a 12-item scale, designed to assess the severity
and frequency of behavioural symptoms in people with dementia
(Cummings 1994).
• The SDAS-9 measures several aspects of behaviour to do
with patient interaction with other people, and physical and
verbal aggression. The scale is a 9-point observation scale
covering outward aggressive behaviour, with total sores ranging
from 0 to 36).
• The “Nurse Observation” scale assesses the incidence of
aggressive behaviour at the moment the behaviour occurs.
• The GIP consists of 14 observational scales to describe
agitated and aggressive behaviour.
Cognition
Herrmann 2007; Porsteinsson 2001; and Tariot 2005 assessed
cognitive functioning using the MMSE.
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Functional performance
Porsteinsson 2001 and Tariot 2005 assessed participants’ func-
tional performance using the Physical Self-Maintenance Scale
(PSMS) (Lawton 1969).
Overall clinical impression
Three studies included a rating of global clinical response of the
participants using the CGI, a 7-point scale with scores ranging
from “very much improved” to “very much worse” (Porsteinsson
2001; Tariot 2001; Tariot 2005). Tariot 2001 reported this as
mean change and Tariot 2005 as number of participants show-
ing improvement. Porsteinsson 2001 reported CGI separately for
therapeutic effect and adverse effects using a different Likert type
scale for each.
Adverse effects
All five studies examined the tolerability, adverse effects, and safety
of valproate preparations.
• Four studies used check-lists of adverse effects (e.g.
drowsiness, nausea, vomiting, diarrhoea, confusion, disturbance
in speech, disturbance of co-ordination, tremor, seizures,
oedema, fever thrombocytopenia), which were reviewed at
regular intervals by interviewing participants and nursing staff;
and by reviewing chart entries (Herrmann 2007; Porsteinsson
2001; Sival 2002; Tariot 2005).
• Tariot 2001 measured adverse events based on the Coding
Symbols for Thesaurus of Adverse Reaction Terms (COSTART
1989).
Effect on carers (carers psychological morbidity)
None of the included studies assessed any aspect of carer burden
or well-being.
Excluded studies
We excluded most studies on the basis of the study design (e.g. not
RCTs). The studies that were excluded, with reasons for exclusion,
are listed in the Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 1.
Allocation
All studies included in this review indicated that participants were
randomly allocated to treatments groups. However, four studies
did not report the process of random sequence generation and
we considered them to be at unclear risk of bias in this domain
(Herrmann 2007; Porsteinsson 2001; Sival 2002; Tariot 2001).
For three of these studies, there was also no specific information
about allocation concealment, but Sival 2002 stated that the “code
was not available to the investigators” and so we rated its risk of
bias due to allocation concealment to be low. Tariot 2005 had a
low risk of allocation bias.
Blinding
Two studies failed to state explicitly whether all staff involved in
the study were blind to the treatment allocation of the participants
(unclear risk of bias; Herrmann 2007; Tariot 2001), and two failed
to state whether research staff completing the outcome measures
were blinded (unclear risk of bias; Herrmann 2007; Sival 2002).
In Porsteinsson 2001, although the physicians having direct re-
sponsibility for participant care and researchers completing study
assessments were blinded, a non-blinded physician, who had no
direct contact with these physicians, adjusted divalproex sodium
dosage based on reports from the blinded raters. Similarly, in Sival
2002, a pharmacist and independent physician reviewed out-of-
range laboratory results, including valproate levels. These staff had
no contact with participants, investigators, the ward team or par-
ticipant’s relatives so we considered that the risk of introducing
bias due to unblinding was low.
Tariot 2001 was described as a double-blind study but total serum
valproate levels were measured weekly and monitored by nursing
staff. It was not stated whether these nursing staff were involved in
the study, so we judged this to pose an unclear risk of performance
bias.
Incomplete outcome data
In Tariot 2001, 54% of the valproate-treated participants dropped
out compared with 29% of control participants; 22% of all partic-
ipants dropped out because of adverse effects, and the study had
to be discontinued prematurely. Further, since participants had
been on therapy for varying periods of time when the study was
terminated, interpretation of the effects of treatment was difficult.
We considered this study at high risk of attrition bias.
Porsteinsson 2001 included data in the analysis from participants
who dropped out of the study, and gave the reasons for the par-
ticipants dropping out (two from the divalproex group, and four
from the placebo group; low risk of attrition bias).
In Tariot 2005, 11/75 participants in the divalproex group and
14/78 participants in the placebo group dropped out of treatment
early, but the reasons for discontinuation were not given. However,
all participants who discontinued prematurely completed final as-
sessments which were included in the analysis, so we considered
the risk of attrition bias to be low.
In Herrmann 2007, two participants dropped out during each
treatment phase but reasons for this were not stated. The study
15Valproate preparations for agitation in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
authors stated that they conducted an intention-to-treat analysis,
but data for all participants was not included in the results table.
We included only the results from the first part of the study in this
review and obtained first-phase data from the study authors for
all participants; for this reason, we considered the risk of attrition
bias to be low.
In Sival 2002, three participants dropped out of the study due to
adverse events in either the placebo or washout periods and these
data were included in the analysis. One participant was excluded
from the analysis due to protocol violation (low risk of attrition
bias).
Selective reporting
We found no published protocols for the included studies. How-
ever, for all included studies, the results of the primary and sec-
ondary outcome measures that were specified in the methods sec-
tions of the papers were reported, as well as the frequency of ad-
verse events. Therefore, we judged all the studies to be at low risk
of selective reporting bias.
Other potential sources of bias
Sival 2002 had a cross-over design. No results from the first phase
of the study were available. The statistical analysis did not take
account of the paired nature of the data (“the t-test for independent
samples is used to analyse the two-period cross-over trial”).
We noted that three of the included studies were supported by
grants from Abbott laboratories - a company which may have had
a vested interest in the efficacy of the treatment - but we did not
rate this as a source of bias (Porsteinsson 2001; Tariot 2001; Tariot
2005).
Effects of interventions
See: Summary of findings for the main comparison Valproate
preparations compared to placebo for agitation in dementia
The included studies varied in the type of valproic acid prepara-
tion, dosage, and duration of therapy. The methods of evaluat-
ing the participants also varied between the studies, with use of
different scales to assess agitation and aggression, and response to
therapy. Tariot 2001 was discontinued due to the disproportion-
ate number of dropouts in the treatment group (54%) as well as a
high proportion in the placebo group (29%), with the results that
not all participants received treatment for the full study period.
Many of these dropouts occurred in the first three weeks (11/47
participants). Due to the high risk of attrition bias caused by the
high dropout rate, we decided to exclude the data from the pooled
analysis in this review. Sival 2002 was a cross-over design and first-
phase data were not available from the published paper, or from
the authors, and so data from this study was also not included in
our analyses.
Agitation and aggression
We were able to pool data on agitation/aggression measured with
the BPRS from two studies and the CMAI from three studies.
A meta-analysis of agitated behaviour, assessed with total BPRS
scores in two studies, showed that there was probably no differ-
ence between valproate and placebo group in total BPRS after six
weeks of treatment (MD 0.23, 95% CI -2.14 to 2.59; 202 partic-
ipants, 2 studies; Analysis 1.1; moderate-quality evidence, down-
graded due to imprecision) (Porsteinsson 2001; Tariot 2005). A
pooled analysis of agitation measured with the agitation factor of
the BPRS confirmed that there was probably no effect of treat-
ment specifically on agitation (MD -0.67, 95% CI -1.49 to 0.15;
202 participants, 2 studies; Analysis 1.2; moderate-quality evi-
dence, downgraded due to imprecision). The quality of evidence
on agitation measured with the CMAI was lower, but meta-anal-
ysis of three studies that reported the change in total CMAI score
between baseline and six weeks also suggested no effect on agi-
tated behaviour (MD -1.84, 95% CI -6.02 to 2.34, 217 partici-
pants, 3 studies; I2 = 52%; Analysis 1.3; very low-quality evidence,
downgraded due to risk of bias, inconsistency, and imprecision)
(Herrmann 2007; Porsteinsson 2001; Tariot 2005). Herrmann
2007 and Porsteinsson 2001 did not state specifically which ver-
sion of the CMAI they used in their studies, we made the assump-
tion that they used the standard 29-item scale. Information from
Tariot 2005 indicated that they also used the 29 item scale de-
spite the paper stating they used a 36 item version of the scale. In
light of the uncertainty regarding which version Tariot 2005 used,
we repeated the pooled analysis of change in total CMAI score
after excluding data from Tariot 2005 (MD 1.96, 95% CI -6.18
to 10.10; 70 participants, 2 studies; very low-quality evidence,
downgraded due to risk of bias, inconsistency, and imprecision).
Single studies only reported the other outcome measures.
Porsteinsson 2001 found that there was probably little or no effect
of divalproex on the hostility factor of the BPRS (MD 0.10, 95%
CI -1.12 to 1.32; 55 participants, 1 study; Analysis 1.4; moderate-
quality evidence, downgraded due to imprecision) or the Overt
aggression total score (MD 0.10, 95% CI -3.42 to 3.62; 55 par-
ticipants, 1 study; Analysis 1.5; moderate-quality evidence, down-
graded due to imprecision). Herrmann 2007 used the NPI. This
showed a clinically important difference in behavioural symptoms
as measured by the NPI total score, favouring the placebo group,
but there was a great deal of uncertainty about this result (MD
15.28, 95% CI -5.19 to 35.75; 14 participants, 1 study; Analysis
1.6; very low-quality evidence, downgraded one level due to risk
of bias and two levels due to imprecision). There was similarly a
high level of uncertainty about the result on the NPI agitation/ag-
gression subscale, which showed no clear evidence of a difference
between groups (MD 1.43, 95% CI -2.48 to 5.34; 14 participants,
1 study; Analysis 1.7; very low-quality evidence, downgraded one
level due to risk of bias and two levels due to imprecision).
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Cognition
Three studies assessed cognitive functioning using the MMSE (
Herrmann 2007; Porsteinsson 2001; Tariot 2005). The quality of
this evidence was very low. but pooled analysis of the data indicated
that there may have been little or no effect of valproate on the
change in MMSE score over the six-week treatment period (MD
-0.70, 95% CI -1.61 to 0.20; 217 participants, 3 studies; Analysis
1.8; very low-quality evidence, downgraded due to risk of bias,
inconsistency, and imprecision).
Functional performance
Porsteinsson 2001 and Tariot 2005 assessed functional ability us-
ing the PSMS. Pooled analysis of the change in total PSMS score
indicated that there was probably little or no effect of valproate on
this outcome (MD 1.19, 95% CI 0.40 to 1.98; 203 participants,
2 studies; Analysis 1.9; moderate-quality evidence, downgraded
due to imprecision).
Overall clinical impression
Three studies included a measure of global clinical change, but we
excluded data from Tariot 2001 due to the very high risk of attri-
tion bias. Tariot 2005 used the CGI as an index of clinical efficacy,
measuring change in participants’ overall clinical condition on a
7-point scale (0 marked improvement to 6 marked worsening).
The number of participants showing improvement was reported
not to differ significantly between the two groups. Porsteinsson
2001 used the CGI to rate “therapeutic effect” on a 4-point scale,
and the presence and clinical significance of adverse effects on a 7-
point scale (from very much improved to very much worse). They
reported no difference between groups in CGI ratings. Because of
the different ways in which the CGI was used was used in these
two studies, we were unable to pool data.
Incidence and severity of adverse effects
Meta-analysis of three studies, all of which used divalproex sodium,
found there may have been a higher rate of adverse effects among
participants treated with divalproex sodium than among partici-
pants in the control group (OR 2.02, 95% CI 1.30 to 3.14; 381
participants, 3 studies; Analysis 2.27; low-quality evidence, down-
graded due to imprecision and inconsistency) (Porsteinsson 2001;
Tariot 2001; Tariot 2005). A fourth study reported that the mean
incidence of adverse effects was low during three weeks of observa-
tion in both sodium valproate (0.17) and placebo (0.02) groups,
but the study provided no description of the types of adverse reac-
tions or actual numbers of adverse events experienced, so we could
not include this study in the meta-analysis (Sival 2002). Data on
adverse effects during the first treatment phase of Herrmann 2007
were not available in the published data or from the authors, but
over the course of both treatment phases, 12 participants experi-
enced at least one adverse event while taking valproate compared
to eight participants while taking placebo. The mean number of
adverse events from valproate was significantly greater than with
placebo.
The descriptions of adverse effects which study authors used var-
ied making pooled analysis of all adverse effects difficult. How-
ever, pooled analysis of adverse effects that were reported in more
than one study indicated that sedation (OR 2.66, 95% CI 1.44 to
4.92; 228 participants, 2 studies; Analysis 2.1; moderate-quality
evidence, downgraded due to imprecision), ’nausea, vomiting and
diarrhoea’ (OR 6.92, 95% CI 2.13 to 22.49; 381 participants, 3
studies; Analysis 2.2; moderate-quality evidence, downgraded due
to imprecision), and UTIs (OR 3.07, 95% CI 1.05 to 8.97; 228
participants, 2 studies; Analysis 2.3; moderate-quality evidence,
downgraded due to imprecision) were more frequently reported
among valproate-treated participants than placebo-treated partic-
ipants. Falls, respiratory, skin or joint problems, and infections
(other than UTI) were no more frequent in valproate-treated than
in placebo-treated participants.
One study reported thrombocytopenia in 6/87 participants in the
valproate group and 0/85 participants in the placebo group (Tariot
2001). One study reported thrombocytopenia in 2/14 partici-
pants during the treatment phase and none in the placebo phase
(Herrmann 2007). In Porsteinsson 2001, 2/28 participants in the
divalproex group had developed a significant decrease in platelet
count, but not to the level of thrombocytopenia. Sival 2002 mon-
itored blood counts, but reported no instances of a drop in platelet
count.
Serious adverse events
The included studies varied in the reporting of serious adverse
events (SAE) during their treatment period. Sival 2002 did not re-
port the incidence of SAE during their study. Herrmann 2007 did
not report numbers of participants who experienced SAE clearly,
but the study stated that two participants in the treatment phase
had falls that rated as SAEs. There was no indication given about
whether these falls were considered related to the study medication
and it was not clear whether these were the only SAEs to occur.
Tariot 2005 also did not report specifically on numbers of SAEs
although there was one death in the drug-treatment group which
was not considered related to the study drug. The authors stated
that most adverse events were rated as mild to moderate in severity
and were judged as not related to the study drug. Porsteinsson
2001 reported four SAEs, one in the placebo group (worsening
of chronic renal failure) and three in the divalproex group (one
with seizure, cerebrovascular accident, and pneumonia; one with
seizure; and one with small bowel obstruction). Tariot 2001 re-
ported one SAE due to hyponatraemia in the divalproex group,
which was thought probably to be related to the study drug. Six
other participants experienced SAEs, five in the divalproex group
and one in the placebo group. These SAEs were four hospitalisa-
tions (for cellulitis, dehydration, pneumonia, myocardial infarc-
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tion, and constipation) and one cerebrovascular accident; all were
considered to be unrelated to the study drug.
Pooled analysis of the number of SAEs for the two studies which
did report data indicated that participants treated with valproate
were more likely to experience SAEs (OR 4.77, 95% CI 1.00
to 22.74; 228 participants, 2 studies; Analysis 2.28; very low-
quality evidence, downgraded due to risk of bias, inconsistency,
and imprecision) (Porsteinsson 2001; Tariot 2001).
Dropouts
All included studies reported that there were participants who
dropped out during the study period. For most studies, the num-
ber of dropouts were not disproportionate between the treatment
and the placebo groups (Porsteinsson 2001: 7% divalproex versus
14% placebo; Sival 2002: 0% valproate versus 5% placebo; Tariot
2005: 15% divalproex versus 18% placebo; Herrmann 2007: 7%
valproate versus 7% placebo). However, in the study by Tariot
2001, a disproportionate number of participants in the treatment
group dropped out of the study (54% divalproex versus 29%
placebo), with 22% from the treatment group compared to only
4% of the placebo group withdrawing due to adverse events. These
adverse events were predominantly related to somnolence but also
included hyponatraemia, accidents, and weight loss. Due to this
disproportionate level of withdrawal in the divalproex group, the
study was terminated early.
D I S C U S S I O N
Summary of main results
We found no evidence of a beneficial effect of valproate on our
primary outcome of agitation or closely related behavioural out-
comes, measured using several outcome scales. Neither did we find
evidence of any important effect on any of our secondary efficacy
outcomes. However, participants taking valproate may have been
at higher risk of adverse effects, including SAEs. These findings
are described in Summary of findings for the main comparison.
Specifically, our results showed that there was probably little or
no effect on agitated and aggressive behaviours as measured by
the BPRS. There was very low-quality evidence using other scales,
but results were consistent with this finding. Pooled analysis also
indicated probably slightly worse function in the valproate-treated
group, on functional ability assessed with the PSMS, of uncertain
clinical importance. We found very low-quality evidence of no
effect on cognition assessed with the MMSE.
Pooled analysis of the numbers of participants who experienced
any adverse effect was limited to three of the included studies
(Porsteinsson 2001; Tariot 2001; Tariot 2005), but indicated that
participants treated with valproate preparations may have been
more likely to experience adverse effects than participants taking
placebo. Likewise, participants treated with valproate preparations
were more likely to experience SAEs, although the quality of this
evidence was very low (data from two studies; Porsteinsson 2001;
Tariot 2001). Individual adverse effects which were found in one
or more studies to be more frequent in the valproate-treated group
were sedation, gastrointestinal symptoms, and UTI.
Overall completeness and applicability of
evidence
The small number of included studies, some of which involved
small numbers of participants, limited the evidence available. This
was further limited since one study closed prematurely and that
separate first-phase data were not available from the cross-over
trials for inclusion in the review analysis (Herrmann 2007 for some
data; Sival 2002).
Because of the limited number of participants, it was not possi-
ble to analyse secondary objectives such as the effect of valproate
therapy on individual manifestations of agitation (e.g. crying out,
wandering) or the influence of age, gender, or degree and type of
dementia on the response to therapy. The small number of in-
cluded studies also meant it was not possible to analyse how the
response to valproate preparations was influenced by dose and du-
ration of treatment.
The premature termination of one study, in which 47 (54%)
treated participants dropped out before the protocol could be com-
pleted, severely limited the confidence that could be placed on the
conclusion of the study authors that divalproex sodium improved
agitation of people with dementia (Tariot 2001). Because so many
of the participants did not complete the study treatment period,
we did not include data from this study in the pooled efficacy
analyses.
Quality of the evidence
We only identified five studies for inclusion in this review and most
varied in the outcome measures used to assess impact of treatment
with valproate preparations on agitated behaviour thus making
comparisons of study outcomes difficult. We found the quality of
evidence for most outcomes measures used to be of low or very low
quality primarily due to risk of bias, imprecision, and inconsis-
tency in the included studies (because of poorly described method-
ology, small sample sizes, and heterogeneity of sample groups and
treatments used).
Methodological and clinical diversity limited opportunities for
pooling data. Specifically, variations in method, type of medica-
tion, dosage, duration of treatment, and use of different outcome
measures in these studies made it difficult to apply meta-analysis.
For example, it was difficult to compare directly studies that em-
ployed short-acting sodium valproate (Sival 2002) or longer-acting
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divalproex sodium (Porsteinsson 2001; Tariot 2001), and in which
the dosage varied more than two-fold (Sival 2002, mean dose 480
mg/day; Tariot 2001, median dose 1000 mg/day; Porsteinsson
2001, mean dose 875 mg/day).
We did not include data from Sival 2002 because we could not
obtain first period data as our protocol required. We considered
that there was a risk of carryover effects. We also considered that
there was a unit of analysis error in the analysis reported in the
paper, which failed to account for the cross-over design.
Potential biases in the review process
It is possible that pooling of clinically diverse studies may have
concealed important benefits or harms.
Agreements and disagreements with other
studies or reviews
The conclusions of this updated review were in keeping with the
NICE evidence summary on the use of valproate preparations
for agitation and aggression in dementia which stated that such
medications were no more effective than placebo, and that adverse
effects were more common in people taking them (NICE 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Robust randomised controlled trial evidence regarding valproate
preparations for aggression in people who have dementia is lim-
ited, and we identified only five studies for inclusion in this review.
Evidence from the five trials, including limited pooled analysis of
data, did not support the use of valproate preparations to manage
agitation in people with dementia, and demonstrated increased
frequency of several types of adverse effect, including serious ad-
verse effects.
From the information available, valproate preparations cannot be
recommended for the treatment of people with dementia with
agitation.
Implications for research
The quality of evidence in this review ranged from moderate to
very low on a range of different outcome measures and overall did
not indicate any benefit of valproate for the treatment of agitation
in people with dementia. As the limited evidence that was avail-
able showed no signal of benefit, further investigation may not be
justified, particularly in light of the increased risk of adverse effects
in this often frail group of people. Research would be better fo-
cused on effective non-pharmacological interventions for this pa-
tient group, or, for those situations where the behaviours present
immediate risk, further evaluation of how other medications, such
as antipsychotics, can be used most effectively and safely.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Herrmann 2007
Methods Randomised, double-blind, placebo-controlled trial. Cross-over design, of 6-week treat-
ment with valproate/placebo, with 2-week washout interval
Participants Setting: residents of 2 long-term care facilities associated with university-affiliated general
hospitals in Canada
Diagnosis: AD
Inclusion criteria: DSM-IV criteria for primary degenerative dementia, and NINCDS-
ADRDA criteria for probable AD of ≥ 1 year’s duration; aged > 55 years; MMSE score
< 15 (i.e. moderate-to-severe cognitive impairment); NPI total score ≥ 8
Exclusion criteria: significant medical or neurological conditions that could account
for cognitive impairment; Hachinski Ischemic Scale score 3; neuroimaging inconsistent
with diagnosis of AD; presence of premorbid or current psychiatric diagnoses. No stated
clinical evaluation to exclude acute medical illness such as delirium
Total number of participants: 14 (12 participants completed, 1 dropout during each
treatment phase. 2 additional participants discontinued placebo early but competed all
study assessments.)
Baseline characteristics
• Age: mean 85.6 years (SD 4.5)
• Women: 43%
• MMSE: mean 4.5 (SD 4.6)
• NPI total score: mean 33.4 (SD 23.6)
• NPI agitation/aggression score: mean 6.4 (SD 3.5)
• CMAI total score: mean 53.4 (SD 15.7)
• Number of participants with antidepressant drugs at screening (%): 2 withdrawn
from antidepressants before study
• Use of cholinesterase inhibitors: not reported
• Use of memantine: not reported
Interventions 6 weeks of valproate/placebo followed by 2 weeks of washout period followed by 6 weeks
of valproate/placebo
Titration of valproate, with a mean daily dose of 1134.6 mg (SD 400.1)
Participants underwent a placebo washout of all psychotropic drugs before randomisation
Outcomes Primary:
• Agitation measured with NPI agitation subscale score mean change at 6 weeks
Secondary:
• BPSD measured by NPI total score, change at 6 weeks
• Agitation measured with CMAI, change at 6 weeks
• Safety and tolerability
Notes Cross-over design and small number of participants urge caution in the interpretation
of the results of this study
Risk of bias
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Herrmann 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised….” (p.
117)
Insufficient information about the se-
quence generation process to permit judge-
ment of low risk or high risk
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of low risk or high risk
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Initial 1 week of single-blind placebo
washout, then “double-blind crossover de-
sign” (p. 117)
Quote: “patients randomised to receive val-
proate liquid suspension or an identical
placebo.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information. No explanation
given regarding who completed outcome
measures. Given that the study was de-
scribed as double-blind, it was likely that
the rater was blind to treatment allocation
but this is not stated explicitly
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/16 participants dropped out prior to ran-
domisation and were not included in anal-
ysis. 1 dropped out during each treatment
phase (reasons not stated). 2 additional
participants discontinued treatment with
placebo early (reasons not stated), but com-
pleted all study assessments. Study authors
stated that intention-to-treat analysis was
completed using last observation carried
forward, but incomplete data reported in
results table
Selective reporting (reporting bias) Low risk Results of the primary and secondary out-
come measures specified in methods were
reported, as well as frequency of adverse
events, but no study protocol was avail-
able to determine the prespecified outcome
measures
Other bias Low risk No other potential source of bias identified.
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Porsteinsson 2001
Methods Multicentre, randomised, double-blind, placebo-controlled study of 6-week treatment
placebo/divalproex sodium
Participants Setting: 7 long-term care facilities in New York
Diagnosis: AD, VaD, or mixed dementia
Inclusion criteria: probable or possible AD (by DSM-IV and NINCDS-ADRDA criteria
or VaD (by DSM-IV) or mixed dementia (by DSM-IV); aged > 60 years; agitation
for a minimum of 2 weeks; BPRS score ≥ 3 on items rating tension, hostility, unco-
operativeness, or excitement
Exclusion criteria: acute medical illness as reflected by history, examination, and labora-
tory testing. Acute medical illness excluded
Best efforts exerted to identify and implement non-pharmacological interventions for
the agitation prior to study consideration
Total number of participants: 56 (1 dropped out between randomisation and treatment
because of agitation, but was included in the analysis)
Baseline characteristics
• Mean age: placebo: 84.7 (SD 6.0) years; divalproex: 85.3 (SD 8.1)
• Women: placebo: 22/28 (79%); divalproex: 17/28 (61%)
• Diagnosis: placebo: AD 75%, VaD 18%, mixed 7%; divalproex: AD 68%, VaD
18%, mixed 14%
• Number of participants on psychotropic drugs at screening (%): placebo: 79%;
divalproex: 68%
• Use of cholinesterase inhibitors: not reported
• Use of memantine: not reported
Interventions Divalproex sodium: titrated to mean dose of 826 mg/day; 6-week course
Placebo
Choral hydrate 250-500 mg given on an as-needed basis.
Psychotropic medication was withdrawn before randomisation.
Outcomes Primary:
• BPRS total score, change over 6 weeks
• BPRS agitation factor, change over 6 weeks
• BPRS hostility factor, change over 6 weeks
• CGI, change over 6 weeks
Secondary:
• Overt Aggression Scale score, change over 6 weeks
• CERAD BRSD weighted, change over 6 weeks
• CMAI total score, change over 6 weeks
• Physical Self-maintenance score, change over 6 weeks
• Safety and tolerability
Notes A physician monitor who did not have access to participants or study personnel deter-
mined the optimal dose of divalproex based on written reports from the blinded raters
Risk of bias
Bias Authors’ judgement Support for judgement
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Porsteinsson 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation was blocked by site, but
no specific information regarding sequence
generation process given to permit judge-
ment of low risk or high risk
Allocation concealment (selection bias) Unclear risk No information given. Insufficient infor-
mation to permit judgement of low risk or
high risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants were blinded to treatment
condition with the exception of a physi-
cian-monitor and a pharmacist, neither of
whom had contact with the participant,
care team, family, or laboratory personnel.
The participant’s optimal dose was deter-
mined by the non-blinded physician on the
basis of written reports of adverse effects
from the blinded raters, written reports de-
scribing change in baseline behavioural tar-
get symptoms received from blinded raters,
and confidential laboratory data
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome measures were completed by
blinded raters.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant was dropped between ran-
domisation and treatment because of agita-
tion, this participant was included in analy-
sis. 2 participants dropped out from the di-
valproex group, due to bowel obstruction,
and due to respiratory and urinary tract in-
fections, delirium, and seizures. 4 partici-
pants dropped out from the placebo group,
due to increased agitation. Data from par-
ticipants who dropped out were included
in analysis. Efficacy data were analysed ac-
cording to intention-to-treat principles, us-
ing last observation carried forward for sub-
jects who dropped out after randomisation
Selective reporting (reporting bias) Low risk Results of the primary and secondary out-
come measures specified in methods were
reported, as well as frequency of adverse
events, but no study protocol was avail-
able to determine the prespecified outcome
measures
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Porsteinsson 2001 (Continued)
Other bias Low risk Study supported by “an unrestricted inves-
tigator-initiated grant from Abbott Labo-
ratories. Divalproex Sodium was donated
by Abbott Park Laboratories.”
Sival 2002
Methods Randomised, double-blind, placebo-controlled, cross-over design study of sodium val-
proate
Participants Setting: psychogeriatric short-stay ward at a psychiatric teaching hospital in the Nether-
lands
Diagnosis: dementia (by DSM-IV and NINCDS-ADRDA criteria)
Inclusion criteria: people with aggressive behaviour and senile dementia according to
the criteria of the DSM-IV and NINCDS-ADRDA and who met Patel’s criteria and
also had a score of 3 on ≥ 1 of the items of the SDAS-9. Aggressive behaviour was
defined according to Patel’s description (Patel 1993): aggressive behaviour is an overt
act, involving the delivery of noxious stimuli to (but not necessarily aimed at) another
object, organism, or self, which is clearly not accidental
Exclusion criteria: another diagnosis besides dementia at Axis 1 of the DSM-IV; epilepsy
or epileptic activity according to EEG; myocardial infarction < 3 months prior to the
study, cardiac arrhythmia requiring acute medical treatment; liver insufficiency, renal
failure, myelodysplasia, and blood dyscrasias; using sodium valproate previously; alcohol
or substance abuse, or both; using depot antipsychotics or fluoxetine within 30 days
before the start of the trial. No stated clinical evaluation to exclude acute medical illness
such as delirium
Total number of participants: 43 (1 participant excluded due to protocol violation, and
3 participants dropped out)
Baseline characteristics
• Age: mean80.4 years (SD 6.8)
• Women: 59.5%
• Diagnosis: AD 54.8%, VaD 9.5%, dementia in PD 2.4%, mixed 31%, other
dementia 2.4%
• MMSE: 11.4 (SD 5.0)
• CDR: light 4.8%, moderate 57.1%, severe 38.1%
• Number of participants on psychotropic drugs at screening (%): not reported
• Use of cholinesterase inhibitors: not reported
• Use of memantine: not reported
Interventions Sodium valproate 240 mg twice daily. Oxazepam 10-30 mg/day given if required for
severe anxiety. Baseline extended by 1 week where SDAS-9 score was not > 2
Psychotropic medication was withdrawn before randomisation.
Baseline period (1 week), placebo period (3 weeks), washout period with placebo (1
week), and treatment period with sodium valproate (3 weeks) - sequence of the treatment
periods was assigned at random
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Sival 2002 (Continued)
Outcomes Primary:
• SDAS-9, mean change at end of each treatment period
• CGI scale, mean change at end of each treatment period
Secondary:
• GIP scale, mean change at end of each treatment period
• Safety and tolerability
Notes Participants who withdrew from the study were excluded from analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the sequence of the treatment peri-
ods was assigned at random. The code was
not accessible for the investigators” (p. 581)
No specific information regarding se-
quence generation process given to permit
judgement of low risk or high risk
Allocation concealment (selection bias) Low risk Quote: “The code was not accessible for the
investigators” (p. 581)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study design. Used a placebo
suspension, identical to the active medi-
cation in appearance, quantity, smell, and
taste. Participants and investigators blinded
to treatment allocation. A pharmacist and
an independent physician dealt with labo-
ratory values, including peak valproate lev-
els, outside the normal range. They had no
contact with the participants, investigators,
the ward team, or participant’s relatives
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind study. Outcome assessments
made by geriatrician and research nurse,
but not explicitly stated if they were blind
to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants were considered dropouts and
excluded from analysis in case of severe
adverse reactions or in case of violation
of the protocol. 1/43 participants left out
of analysis due to protocol violation, and
there were 2 dropouts during placebo pe-
riod, and 1 dropout during washout period
(reasons given and not associated with val-
proate treatment) and not included in anal-
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Sival 2002 (Continued)
ysis
Selective reporting (reporting bias) Low risk Results of the primary and secondary out-
come measures specified in methods were
reported, as well as frequency of adverse
events, but no study protocol was avail-
able to determine the prespecified outcome
measures
Other bias Low risk No other potential source of bias identified.
Tariot 2001
Methods 6-week randomised, double-blind, placebo-controlled, parallel-group, multicentre study
Participants Setting: nursing home residents in USA
Diagnosis: probable or possible AD type or VaD
Inclusion criteria: residents of long-term care facilities, aged ≥ 65 years; diagnosis that
met DSM-IV criteria for DAT or VaD, or both; exhibited manic symptoms. Manic
symptoms defined using the Bech-Rafaelsen Mania Scale and 6 items of the BPRS.
Participants were required to have a BRMS total score ≥ 15; BPRS score ≥ 3 on ≥ 2 of the
following items: tension, grandiosity, hostility, suspiciousness, unco-operativeness, and
excitement; and BPRS total score ≥ 15; people had to be able to take oral medications;
expected to remain in the same facility throughout the study
Exclusion criteria: dementia other than DAT or VaD, or both; delirium; seizure disor-
ders; uncontrolled gastrointestinal, renal, hepatic, endocrine, cardiovascular, pulmonary,
immunological, or haematological disease; history of alcohol abuse or substance abuse;
history of, or current, hepatitis A, B, or C infection or pancreatitis; and platelet count
< 100 × 109/L prior to randomisation; acute systemic medical disorders that could con-
found interpretation of results or affect compliance; medical conditions requiring the
continuous use of medication that would interfere with the assessment of safety or effi-
cacy of divalproex sodium; delirium
Total number of participants: 173 (87 divalproex, 85 placebo). 1 participant excluded
after randomisation as they could not swallow the study medication
Baseline characteristics
• Mean age: divalproex: 83.1 (SD 6.7) years, placebo: 83.6 (SD 7.5) years
• Women: divalproex: 66%, placebo: 64%
• MMSE: divalproex: 7.1 (SD 0.75), placebo: 7.7 (SD 0.77)
• Number of participants on psychotropic drugs at screening (%): not reported
• Use of cholinesterase inhibitors: allowed, if on stable dose
• Use of memantine: not reported
Interventions Divalproex sodium: starting dose 125 mg twice daily, titrated in increments of 125 mg/
day to target dose of 20-30 mg/kg. Median dose 1000 mg/day
Psychotropic medication was withdrawn at least 7 days before randomisation. Lo-
razepam, oxazepam, or chloral hydrate were permitted as needed
29Valproate preparations for agitation in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tariot 2001 (Continued)
Outcomes Primary:
• BRMS (11-item observer-based scale that rates the severity of manic symptoms),
change at end point
• CMAI, change at end point
• CMAI verbally agitated behaviour subscale, change at end point
• CMAI aggressive behaviour subscale, change at end point
• CMAI physically non-aggressive behaviour subscale, change at end point
• BPRS, change at end point
• CGI, change at end point
Secondary:
• Safety and tolerability
Notes Study terminated prematurely due to a high number of dropouts in the active treatment
group compared to placebo. 54% of divalproex sodium-treated participants dropped out
compared to 29% of placebo-treated participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Following screening/washout pe-
riod patients were randomly assigned in a
1:1 ratio” (p. 54). Insufficient information
about the sequence generation process to
permit judgement of low risk or high risk
Allocation concealment (selection bias) Unclear risk No information given. Insufficient infor-
mation to permit judgement of low risk or
high risk
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as a double-blind study but ex-
plicit statement that all staff were blinded
to allocation not made except for the fact
that the clinicians completing the out-
come assessment measures were blinded.
Total serum valproate levels were measured
weekly and monitored by nursing staff - it
was not stated whether these nursing staff
were involved with the study/blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinician who completed the outcome as-
sessment measures were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Based on an interim analysis indicating a
disproportionate number of dropouts (due
to adverse events) in the active-treatment
group versus the placebo group, the trial
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Tariot 2001 (Continued)
was suspended (47/87 participants in di-
valproex group and 25/85 participants in
placebo group withdrew prematurely. 22%
of participants in divalproex group vs 4%
in participants in placebo group due to ad-
verse effects. Intention-to-treat analysis car-
ried out using last observation carried for-
ward method. For those participants who
discontinued early, final assessment carried
out on the last day they were in the study.
The previous assessment was used as an es-
timate of the missing assessment
Selective reporting (reporting bias) Low risk Results of the primary and secondary out-
come measures specified in methods were
reported, as well as frequency of adverse
events, but no study protocol was avail-
able to determine the prespecified outcome
measures
Other bias Low risk This study was supported by a grant from
Abbott Laboratories
Tariot 2005
Methods Prospective, multicentre, randomised, double-blind, placebo-controlled, parallel-arm,
flexible-dose study
Participants Setting: nursing home residents in USA
Diagnosis: AD
Inclusion criteria: diagnosis of probable or possible AD according to the NINCDS-
ADRDA criteria; MMSE score 4-24; aged > 49 years; residing in a nursing home; and
having at least a 2-week history of agitation associated with a total score > 14 on the
18-item BPRS and score > 2 on items assessing tension, hostility, unco-operativeness, or
excitement at screening and baseline. People were ambulatory or ambulatory-aided, and
in stable medical condition
Exclusion criteria: clinically significant active medical conditions, other psychiatric or
CNS disorders; modified Hachinski Ischemia Score. Excluded “clinically significant
active medical conditions, other psychiatric or CNS disorders.”
Total number of participants: 153 (75 divalproex sodium, 78 placebo)
Baseline characteristics
• Mean age: placebo: 83.9 (SD 5.9) years, divalproex: 84.2 (SD 6.6) years
• Women: placebo: 73%, divalproex: 63%
• MMSE: placebo: 10.8 (SD 5.4), divalproex: 10.5 (SD 4.9)
• BPRS agitation score, mean: placebo: 8.2 (SD 3.3), divalproex: 8.3 (SD 3.0)
• BPRS total score, mean: placebo: 33.4 (SD 10.0), divalproex: 35.0 (SD 9.1)
• CMAI total score, mean: placebo: 36.4 (SD 15.8), divalproex: 35.6 (SD 16.4)
• PSMS score, mean: placebo: 17.8 (SD 5.0), divalproex: 17.5 (SD 5.2)
• Number of participants on psychotropic drugs at screening (%): not reported
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Tariot 2005 (Continued)
• Use of cholinesterase inhibitors: permitted
• Use of memantine: not reported
Interventions Divalproex sodium delayed-release tablets or placebo given for 6 weeks. Dosage titrated
to 500-1000 mg/day
All psychoactive drugs stopped 7 days prior to randomisation
Psychotropic medication was withdrawn at least 7 days before randomisation. Zolpidem
or lorazepam (or both) were permitted for severe agitation or sleep-induction as needed
Outcomes Primary:




• CGIC (index of clinical efficacy), change between baseline and 3 and 6 weeks
• CMAI, change between baseline and 3 and 6 weeks
• PSMS, change between baseline and 6 weeks
• MMSE, change between baseline and 6 weeks
• Frequency of rescue medication
• Safety and tolerability
Notes Study represents the extension of an earlier pilot study that investigated the safety and
tolerability of divalproex (Porsteinsson 2001). The authors concluded that diarrhoea and
decreased platelet counts were more common among divalproex-treated participants and
that divalproex sodium offered no advantage, compared with placebo, in the management
of people with dementia with agitation and should not be used as a first-line treatment
for this condition
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were assigned to one
of two treatment groups in permuted
blocks of 4, in accordance with a randomi-
sation list created and maintained by the
ADCS data management centre. Investiga-
tors sequentially assigned a randomisation
number to each participant. No individ-
ual randomisation code was revealed dur-
ing the trial” (p. 2)
Allocation concealment (selection bias) Low risk The randomisation list was created and
maintained by the ADCS data manage-
ment centre. No individual randomisation
code was revealed during the trial
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Tariot 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were assigned to double-blind
treatment. All investigators blinded to
treatment allocation. Drug and placebo
tablets were visually identical. Masked val-
proate levels were obtained
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All investigators blinded, study authors
stated that no individual randomisation
code was broken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11/75 participants in divalproex group and
14/78 participants in placebo group dis-
continued treatment early (specific rea-
sons for discontinuation not given). Partic-
ipants who discontinued prematurely were
seen for a final evaluation. Primary analysis
performed according to intention-to-treat
principle
Selective reporting (reporting bias) Low risk Results of the primary and secondary out-
come measures specified in methods were
reported, as well as frequency of adverse
events, but no study protocol was avail-
able to determine the prespecified outcome
measures
Other bias Low risk Quote: “Laboratories Inc provided unre-
stricted supplemental and material support
for this study.”
AD: Alzheimer’s disease; ADCS: Alzheimer’s Disease Cooperative Study Activities ; BPRS: Brief Psychiatric Rating Scale; BPSD:
behavioural and psychological symptoms associated with dementia; CDR: Clinical Dementia Rating; CERAD: Consortium to
Establish a Registry for Alzheimer’s Disease; CMAI: Cohen-Mansfield Agitation Index; CNS: central nervous system; DAT: dementia
of the Alzheimer type; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EEG: electroencephalograph;
GIP: Behavior Observation Scale of Intramural Psychogeriatric Patients; MMSE: Mini-Mental State Examination; NINCDS-
ADRDA: National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders
Association; NPI: Neuropsychiatric Inventory; PD: Parkinson’s disease; SD: standard deviation; SDAS-9: 9-item Social Dysfunction
and Agitation Scale; VaD: vascular dementia.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Forester 2007 Not randomised, no concealed allocation
Goldberg 1999 Not randomised placebo controlled
Gupta 1998 Not randomised placebo controlled
Haas 1997 Not randomised placebo controlled
Horne 1995 Not randomised placebo controlled
Kasckow 1997 Not randomised placebo controlled
Lott 1995 Not randomised placebo controlled
Mazure 1992 Not randomised placebo controlled
Mellow 1993 Not randomised placebo controlled
Narayan 1997 Not randomised placebo controlled
Niedermier 1998 Not randomised placebo controlled
Porsteinsson 1997 Not randomised placebo controlled
Sandborn 1995 Not randomised placebo controlled
Sival 1994 Not randomised placebo controlled
Takahashi 1996 Not randomised placebo controlled
Tariot 2002 Not randomised placebo controlled
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D A T A A N D A N A L Y S E S
Comparison 1. Valproate preparations versus placebo




participants Statistical method Effect size
1 Brief Psychiatric Rating Scale
(BPRS) total score. Change
from baseline at 6 weeks
(intention to treat (ITT))
2 203 Mean Difference (IV, Fixed, 95% CI) 0.23 [-2.14, 2.59]
2 BPRS agitation factor. Change
from baseline at 6 weeks (ITT)
2 203 Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.49, 0.15]
3 Cohen-Mansfield Agitation
Index. Total Score. Change
from baseline at 6 weeks (ITT)
3 217 Mean Difference (IV, Fixed, 95% CI) -1.84 [-6.02, 2.34]
4 BPRS hostility factor. Change
from baseline at 6 weeks (ITT)
1 55 Mean Difference (IV, Fixed, 95% CI) 0.10 [-1.12, 1.32]
5 Overt Aggression Scale total
score. Change from baseline at
6 weeks (ITT)
1 55 Mean Difference (IV, Fixed, 95% CI) 0.10 [-3.42, 3.62]
6 Neuropsychiatric Inventory total
score. Change from baseline at
6 weeks (ITT)
1 14 Mean Difference (IV, Fixed, 95% CI) 15.28 [-5.19, 35.75]
7 Neuropsychiatric Inventory
Agitation/Aggression subscore.
Change from baseline at 6
weeks (ITT)
1 14 Mean Difference (IV, Fixed, 95% CI) 1.43 [-2.48, 5.34]
8 Mini-Mental State Examination
total score. Change from
baseline at 6 weeks (ITT)
3 217 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.61, 0.20]
9 Physical Self-Maintenance Scale
total score. Change from
baseline at 6 weeks (ITT)
2 203 Mean Difference (IV, Fixed, 95% CI) 1.19 [0.40, 1.98]
Comparison 2. Divalproex versus placebo




participants Statistical method Effect size
1 Total number of participants
with sedation at 6 weeks
2 228 Odds Ratio (M-H, Fixed, 95% CI) 2.66 [1.44, 4.92]
2 Total number of participants
with nausea, vomiting, or
diarrhoea at 6 weeks
3 381 Odds Ratio (M-H, Fixed, 95% CI) 6.92 [2.13, 22.49]
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3 Total number of participants
with a urinary tract infection
by 6 weeks
2 228 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [1.05, 8.97]
4 Total number of participants
who had falls by 6 weeks
2 209 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.71, 2.79]
5 Total number of participants
with general disorders by 6
weeks
1 153 Odds Ratio (M-H, Fixed, 95% CI) 2.14 [1.05, 4.36]
6 Total number of participants
with postural instability by 6
weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 4.5 [0.47, 43.09]
7 Total number of participants
with weakness by 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 10.47 [0.54, 204.32]
8 Total number of participants
with cardiovascular problems
by 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 2.08 [0.18, 24.31]
9 Total number of participants
with oedema by 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 7.82 [0.39, 158.87]
10 Total number of participants
with a fever by 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 7.82 [0.39, 158.87]
11 Total number of participants
with a respiratory problem by 6
weeks
2 209 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.33, 2.46]
12 Total number of participants
with ataxia at 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.28, 6.87]
13 Total number of participants
with a skin problem at 6 weeks
3 381 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.55, 1.91]
14 Total number of participants
with trauma (other than falls)
by 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.10, 4.17]
15 Total number of participants
with thrombocytopenia by 6
weeks
1 172 Odds Ratio (M-H, Fixed, 95% CI) 13.64 [0.76, 245.98]
16 Total number of participants
with joint problems by 6 weeks
2 209 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.35, 2.05]
17 Total number of participants
with other infection by 6 weeks
3 381 Odds Ratio (M-H, Fixed, 95% CI) 1.31 [0.70, 2.45]
18 Total number of participants
with hallucinations by 6 weeks
1 56 Odds Ratio (M-H, Fixed, 95% CI) 3.11 [0.12, 79.64]
19 Total number of participants
with accidental injury by 6
weeks
2 325 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.84, 2.50]
20 Total number of participants
with anorexia by 6 weeks
1 172 Odds Ratio (M-H, Fixed, 95% CI) 2.53 [0.92, 6.92]
21 Total number of participants
with weight loss by 6 weeks
1 172 Odds Ratio (M-H, Fixed, 95% CI) 2.77 [0.71, 10.81]
22 Total number of participants
with dehydration by 6 weeks
1 172 Odds Ratio (M-H, Fixed, 95% CI) 3.63 [0.73, 18.01]
23 Total number of participants
with metabolism and
nutritional disorders by 6 weeks
1 153 Odds Ratio (M-H, Fixed, 95% CI) 3.30 [0.65, 16.92]
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24 Total number of participants
with psychiatric disorders by 6
weeks
1 153 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [0.71, 3.66]
25 Total number of participants
with other gastrointestinal
problem by 6 weeks
2 208 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.70, 2.97]
26 Total numbers of participants
with nervous system disorders
by 6 weeks
1 153 Odds Ratio (M-H, Fixed, 95% CI) 2.42 [1.01, 5.80]
27 Total number of participants
with any adverse event by 6
weeks
3 381 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [1.30, 3.14]
28 Total number of participants
with serious adverse events by 6
weeks
2 228 Odds Ratio (M-H, Fixed, 95% CI) 4.77 [1.00, 22.74]
Analysis 1.1. Comparison 1 Valproate preparations versus placebo, Outcome 1 Brief Psychiatric Rating
Scale (BPRS) total score. Change from baseline at 6 weeks (intention to treat (ITT)).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 1 Brief Psychiatric Rating Scale (BPRS) total score. Change from baseline at 6 weeks (intention to treat (ITT))





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Porsteinsson 2001 28 -6.9 (8.2) 28 -5.9 (6.6) 36.8 % -1.00 [ -4.90, 2.90 ]
Tariot 2005 72 -4.19 (9.3) 75 -5.13 (9.1) 63.2 % 0.94 [ -2.04, 3.92 ]
Total (95% CI) 100 103 100.0 % 0.23 [ -2.14, 2.59 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours divalproex Favours placebo
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Analysis 1.2. Comparison 1 Valproate preparations versus placebo, Outcome 2 BPRS agitation factor.
Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 2 BPRS agitation factor. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Porsteinsson 2001 28 -3.6 (2.9) 28 -2.3 (2.5) 33.3 % -1.30 [ -2.72, 0.12 ]
Tariot 2005 72 -2.08 (3.1) 75 -1.72 (3.1) 66.7 % -0.36 [ -1.36, 0.64 ]
Total (95% CI) 100 103 100.0 % -0.67 [ -1.49, 0.15 ]
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Valproate preparations versus placebo, Outcome 3 Cohen-Mansfield Agitation
Index. Total Score. Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 3 Cohen-Mansfield Agitation Index. Total Score. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Herrmann 2007 7 11.7 (13.9) 7 -2.7 (17) 6.6 % 14.40 [ -1.87, 30.67 ]
Porsteinsson 2001 28 -9.5 (22.2) 28 -7.3 (12.3) 19.8 % -2.20 [ -11.60, 7.20 ]
Tariot 2005 72 -6.7 (15.6) 75 -3.5 (14.5) 73.6 % -3.20 [ -8.07, 1.67 ]
Total (95% CI) 107 110 100.0 % -1.84 [ -6.02, 2.34 ]
Heterogeneity: Chi2 = 4.13, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Valproate preparations versus placebo, Outcome 4 BPRS hostility factor.
Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 4 BPRS hostility factor. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Porsteinsson 2001 28 -1.5 (2.5) 27 -1.6 (2.1) 100.0 % 0.10 [ -1.12, 1.32 ]
Total (95% CI) 28 27 100.0 % 0.10 [ -1.12, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Valproate preparations versus placebo, Outcome 5 Overt Aggression Scale
total score. Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 5 Overt Aggression Scale total score. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Porsteinsson 2001 28 -4.8 (7) 27 -4.9 (6.3) 100.0 % 0.10 [ -3.42, 3.62 ]
Total (95% CI) 28 27 100.0 % 0.10 [ -3.42, 3.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Valproate preparations versus placebo, Outcome 6 Neuropsychiatric Inventory
total score. Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 6 Neuropsychiatric Inventory total score. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Herrmann 2007 7 11.14 (16.24) 7 -4.14 (22.36) 100.0 % 15.28 [ -5.19, 35.75 ]
Total (95% CI) 7 7 100.0 % 15.28 [ -5.19, 35.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Valproate preparations versus placebo, Outcome 7 Neuropsychiatric Inventory
Agitation/Aggression subscore. Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 7 Neuropsychiatric Inventory Agitation/Aggression subscore. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Herrmann 2007 7 1 (3.51) 7 -0.43 (3.95) 100.0 % 1.43 [ -2.48, 5.34 ]
Total (95% CI) 7 7 100.0 % 1.43 [ -2.48, 5.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Valproate preparations versus placebo, Outcome 8 Mini-Mental State
Examination total score. Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 8 Mini-Mental State Examination total score. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Herrmann 2007 7 1.71 (4.57) 7 -2.29 (3.64) 4.4 % 4.00 [ -0.33, 8.33 ]
Porsteinsson 2001 28 -1.8 (5.6) 28 -1.6 (6.3) 8.4 % -0.20 [ -3.32, 2.92 ]
Tariot 2005 72 -0.85 (2.8) 75 0.14 (3.2) 87.2 % -0.99 [ -1.96, -0.02 ]
Total (95% CI) 107 110 100.0 % -0.70 [ -1.61, 0.20 ]
Heterogeneity: Chi2 = 4.97, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Valproate preparations versus placebo, Outcome 9 Physical Self-Maintenance
Scale total score. Change from baseline at 6 weeks (ITT).
Review: Valproate preparations for agitation in dementia
Comparison: 1 Valproate preparations versus placebo
Outcome: 9 Physical Self-Maintenance Scale total score. Change from baseline at 6 weeks (ITT)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Porsteinsson 2001 28 0.4 (2.6) 28 -0.2 (2.2) 39.2 % 0.60 [ -0.66, 1.86 ]
Tariot 2005 72 1.73 (3.5) 75 0.16 (2.7) 60.8 % 1.57 [ 0.56, 2.58 ]
Total (95% CI) 100 103 100.0 % 1.19 [ 0.40, 1.98 ]
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Divalproex versus placebo, Outcome 1 Total number of participants with
sedation at 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 1 Total number of participants with sedation at 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 11/28 3/28 14.1 % 5.39 [ 1.31, 22.25 ]
Tariot 2001 31/87 17/85 85.9 % 2.21 [ 1.11, 4.41 ]
Total (95% CI) 115 113 100.0 % 2.66 [ 1.44, 4.92 ]
Total events: 42 (Divalproex), 20 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 3.13 (P = 0.0018)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Divalproex versus placebo, Outcome 2 Total number of participants with
nausea, vomiting, or diarrhoea at 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 2 Total number of participants with nausea, vomiting, or diarrhoea at 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 7/28 2/28 52.0 % 4.33 [ 0.81, 23.10 ]
Tariot 2001 6/87 1/85 32.7 % 6.22 [ 0.73, 52.83 ]
Tariot 2005 7/75 0/78 15.3 % 17.19 [ 0.96, 306.53 ]
Total (95% CI) 190 191 100.0 % 6.92 [ 2.13, 22.49 ]
Total events: 20 (Divalproex), 3 (Placebo)
Heterogeneity: Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Divalproex versus placebo, Outcome 3 Total number of participants with a
urinary tract infection by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 3 Total number of participants with a urinary tract infection by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 5/28 3/28 57.6 % 1.81 [ 0.39, 8.44 ]
Tariot 2001 9/87 2/85 42.4 % 4.79 [ 1.00, 22.86 ]
Total (95% CI) 115 113 100.0 % 3.07 [ 1.05, 8.97 ]
Total events: 14 (Divalproex), 5 (Placebo)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Divalproex versus placebo, Outcome 4 Total number of participants who had
falls by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 4 Total number of participants who had falls by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 7/28 5/28 27.2 % 1.53 [ 0.42, 5.58 ]
Tariot 2005 16/75 13/78 72.8 % 1.36 [ 0.60, 3.05 ]
Total (95% CI) 103 106 100.0 % 1.40 [ 0.71, 2.79 ]
Total events: 23 (Divalproex), 18 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Divalproex versus placebo, Outcome 5 Total number of participants with
general disorders by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 5 Total number of participants with general disorders by 6 weeks
Study or subgroup Divalproex Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2005 28/75 17/78 100.0 % 2.14 [ 1.05, 4.36 ]
Total (95% CI) 75 78 100.0 % 2.14 [ 1.05, 4.36 ]
Total events: 28 (Divalproex), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Divalproex versus placebo, Outcome 6 Total number of participants with
postural instability by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 6 Total number of participants with postural instability by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 4/28 1/28 100.0 % 4.50 [ 0.47, 43.09 ]
Total (95% CI) 28 28 100.0 % 4.50 [ 0.47, 43.09 ]
Total events: 4 (Divalproex), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Divalproex versus placebo, Outcome 7 Total number of participants with
weakness by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 7 Total number of participants with weakness by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 4/28 0/28 100.0 % 10.47 [ 0.54, 204.32 ]
Total (95% CI) 28 28 100.0 % 10.47 [ 0.54, 204.32 ]
Total events: 4 (Divalproex), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Divalproex versus placebo, Outcome 8 Total number of participants with
cardiovascular problems by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 8 Total number of participants with cardiovascular problems by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 2/28 1/28 100.0 % 2.08 [ 0.18, 24.31 ]
Total (95% CI) 28 28 100.0 % 2.08 [ 0.18, 24.31 ]
Total events: 2 (Divalproex), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Divalproex versus placebo, Outcome 9 Total number of participants with
oedema by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 9 Total number of participants with oedema by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 3/28 0/28 100.0 % 7.82 [ 0.39, 158.87 ]
Total (95% CI) 28 28 100.0 % 7.82 [ 0.39, 158.87 ]
Total events: 3 (Divalproex), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours divalproex Favours placebo
48Valproate preparations for agitation in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.10. Comparison 2 Divalproex versus placebo, Outcome 10 Total number of participants with a
fever by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 10 Total number of participants with a fever by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 3/28 0/28 100.0 % 7.82 [ 0.39, 158.87 ]
Total (95% CI) 28 28 100.0 % 7.82 [ 0.39, 158.87 ]
Total events: 3 (Divalproex), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Divalproex versus placebo, Outcome 11 Total number of participants with a
respiratory problem by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 11 Total number of participants with a respiratory problem by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 5/28 0/28 5.0 % 13.34 [ 0.70, 253.89 ]
Tariot 2005 2/75 8/78 95.0 % 0.24 [ 0.05, 1.17 ]
Total (95% CI) 103 106 100.0 % 0.90 [ 0.33, 2.46 ]
Total events: 7 (Divalproex), 8 (Placebo)
Heterogeneity: Chi2 = 5.90, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Divalproex versus placebo, Outcome 12 Total number of participants with
ataxia at 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 12 Total number of participants with ataxia at 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 4/28 3/28 100.0 % 1.39 [ 0.28, 6.87 ]
Total (95% CI) 28 28 100.0 % 1.39 [ 0.28, 6.87 ]
Total events: 4 (Divalproex), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Divalproex versus placebo, Outcome 13 Total number of participants with a
skin problem at 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 13 Total number of participants with a skin problem at 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 4/28 3/28 13.0 % 1.39 [ 0.28, 6.87 ]
Tariot 2001 5/87 4/85 19.3 % 1.23 [ 0.32, 4.76 ]
Tariot 2005 15/75 17/78 67.6 % 0.90 [ 0.41, 1.96 ]
Total (95% CI) 190 191 100.0 % 1.03 [ 0.55, 1.91 ]
Total events: 24 (Divalproex), 24 (Placebo)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Divalproex versus placebo, Outcome 14 Total number of participants with
trauma (other than falls) by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 14 Total number of participants with trauma (other than falls) by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 2/28 3/28 100.0 % 0.64 [ 0.10, 4.17 ]
Total (95% CI) 28 28 100.0 % 0.64 [ 0.10, 4.17 ]
Total events: 2 (Divalproex), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours divalproex Favours placebo
51Valproate preparations for agitation in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.15. Comparison 2 Divalproex versus placebo, Outcome 15 Total number of participants with
thrombocytopenia by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 15 Total number of participants with thrombocytopenia by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2001 6/87 0/85 100.0 % 13.64 [ 0.76, 245.98 ]
Total (95% CI) 87 85 100.0 % 13.64 [ 0.76, 245.98 ]
Total events: 6 (Divalproex), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Divalproex versus placebo, Outcome 16 Total number of participants with
joint problems by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 16 Total number of participants with joint problems by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 1/28 3/28 27.1 % 0.31 [ 0.03, 3.16 ]
Tariot 2005 9/75 9/78 72.9 % 1.05 [ 0.39, 2.80 ]
Total (95% CI) 103 106 100.0 % 0.85 [ 0.35, 2.05 ]
Total events: 10 (Divalproex), 12 (Placebo)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Divalproex versus placebo, Outcome 17 Total number of participants with
other infection by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 17 Total number of participants with other infection by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 1/28 1/28 5.6 % 1.00 [ 0.06, 16.82 ]
Tariot 2001 9/87 10/85 53.1 % 0.87 [ 0.33, 2.25 ]
Tariot 2005 15/75 9/78 41.3 % 1.92 [ 0.78, 4.69 ]
Total (95% CI) 190 191 100.0 % 1.31 [ 0.70, 2.45 ]
Total events: 25 (Divalproex), 20 (Placebo)
Heterogeneity: Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Divalproex versus placebo, Outcome 18 Total number of participants with
hallucinations by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 18 Total number of participants with hallucinations by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 1/28 0/28 100.0 % 3.11 [ 0.12, 79.64 ]
Total (95% CI) 28 28 100.0 % 3.11 [ 0.12, 79.64 ]
Total events: 1 (Divalproex), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Divalproex versus placebo, Outcome 19 Total number of participants with
accidental injury by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 19 Total number of participants with accidental injury by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2001 29/87 21/85 65.3 % 1.52 [ 0.78, 2.96 ]
Tariot 2005 11/75 9/78 34.7 % 1.32 [ 0.51, 3.39 ]
Total (95% CI) 162 163 100.0 % 1.45 [ 0.84, 2.50 ]
Total events: 40 (Divalproex), 30 (Placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Divalproex versus placebo, Outcome 20 Total number of participants with
anorexia by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 20 Total number of participants with anorexia by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2001 14/87 6/85 100.0 % 2.53 [ 0.92, 6.92 ]
Total (95% CI) 87 85 100.0 % 2.53 [ 0.92, 6.92 ]
Total events: 14 (Divalproex), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 Divalproex versus placebo, Outcome 21 Total number of participants with
weight loss by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 21 Total number of participants with weight loss by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2001 8/87 3/85 100.0 % 2.77 [ 0.71, 10.81 ]
Total (95% CI) 87 85 100.0 % 2.77 [ 0.71, 10.81 ]
Total events: 8 (Divalproex), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours divalproex Favours placebo
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Analysis 2.22. Comparison 2 Divalproex versus placebo, Outcome 22 Total number of participants with
dehydration by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 22 Total number of participants with dehydration by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2001 7/87 2/85 100.0 % 3.63 [ 0.73, 18.01 ]
Total (95% CI) 87 85 100.0 % 3.63 [ 0.73, 18.01 ]
Total events: 7 (Divalproex), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours divalproex Favours placebo
Analysis 2.23. Comparison 2 Divalproex versus placebo, Outcome 23 Total number of participants with
metabolism and nutritional disorders by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 23 Total number of participants with metabolism and nutritional disorders by 6 weeks
Study or subgroup Divalproex Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2005 6/75 2/78 100.0 % 3.30 [ 0.65, 16.92 ]
Total (95% CI) 75 78 100.0 % 3.30 [ 0.65, 16.92 ]
Total events: 6 (Divalproex), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours divalproex Favours placebo
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Analysis 2.24. Comparison 2 Divalproex versus placebo, Outcome 24 Total number of participants with
psychiatric disorders by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 24 Total number of participants with psychiatric disorders by 6 weeks
Study or subgroup Divalproex Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2005 17/75 12/78 100.0 % 1.61 [ 0.71, 3.66 ]
Total (95% CI) 75 78 100.0 % 1.61 [ 0.71, 3.66 ]
Total events: 17 (Divalproex), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours divalproex Favours placebo
Analysis 2.25. Comparison 2 Divalproex versus placebo, Outcome 25 Total number of participants with
other gastrointestinal problem by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 25 Total number of participants with other gastrointestinal problem by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 4/28 2/27 14.1 % 2.08 [ 0.35, 12.45 ]
Tariot 2005 17/75 14/78 85.9 % 1.34 [ 0.61, 2.96 ]
Total (95% CI) 103 105 100.0 % 1.44 [ 0.70, 2.97 ]
Total events: 21 (Divalproex), 16 (Placebo)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours divalproex Favours placebo
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Analysis 2.26. Comparison 2 Divalproex versus placebo, Outcome 26 Total numbers of participants with
nervous system disorders by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 26 Total numbers of participants with nervous system disorders by 6 weeks
Study or subgroup Divalproex Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tariot 2005 18/75 9/78 100.0 % 2.42 [ 1.01, 5.80 ]
Total (95% CI) 75 78 100.0 % 2.42 [ 1.01, 5.80 ]
Total events: 18 (Divalproex), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours divalproex Favours placebo
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Analysis 2.27. Comparison 2 Divalproex versus placebo, Outcome 27 Total number of participants with any
adverse event by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 27 Total number of participants with any adverse event by 6 weeks
Study or subgroup Divalproex placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 19/28 9/28 10.3 % 4.46 [ 1.45, 13.68 ]
Tariot 2001 72/87 53/85 32.9 % 2.90 [ 1.43, 5.89 ]
Tariot 2005 52/75 53/78 56.8 % 1.07 [ 0.54, 2.11 ]
Total (95% CI) 190 191 100.0 % 2.02 [ 1.30, 3.14 ]
Total events: 143 (Divalproex), 115 (placebo)
Heterogeneity: Chi2 = 6.27, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours divalproex Favours placebo
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Analysis 2.28. Comparison 2 Divalproex versus placebo, Outcome 28 Total number of participants with
serious adverse events by 6 weeks.
Review: Valproate preparations for agitation in dementia
Comparison: 2 Divalproex versus placebo
Outcome: 28 Total number of participants with serious adverse events by 6 weeks
Study or subgroup Divalproex Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porsteinsson 2001 3/28 1/28 48.7 % 3.24 [ 0.32, 33.22 ]
Tariot 2001 6/87 1/85 51.3 % 6.22 [ 0.73, 52.83 ]
Total (95% CI) 115 113 100.0 % 4.77 [ 1.00, 22.74 ]
Total events: 9 (Divalproex), 2 (Placebo)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours divalproex Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics
Name Country Population Mean age
(years)
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BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression Scale; CMAI: Cohen-Mansfield Agitation Inventory; DSM-IV:
Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GIP: Behavior Observation Scale of Intramural Psychogeriatric
Patients; MMSE: Mini-Mental State Examination; n: number of participants; NINDCDS-ADRDA: National Institute of Neuro-
logical and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association; SDAS-9: 9-item Social
Dysfunction and Agitation Scale; VaD: vascular dementia.
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Table 2. Outcomes, instruments, and studies
Outcomes Instruments Studies
Agitation and aggression CMAI Herrmann 2007; Porsteinsson 2001; Tariot
2001; Tariot 2005
BPRS or agitation and hostility subscale, or
both
Porsteinsson 2001
BPRS Tariot 2001; Tariot 2005
Neuropsychiatric Inventory (NPI) Herrmann 2007
Social Dysfunction and Aggression-9 Scale
(SDAS-9)
Sival 2002
Clinical Global Impression Scale (CGI) Sival 2002
Nurse Observation Scale Sival 2002
Patel’s Method Sival 2002
Overt Aggression Scale Porsteinsson 2001
Other types of disturbed behaviour Behavior Scale for Intramural Psychogeriatric
Patients (GIP)
Sival 2002
Cognition MMSE Herrmann 2007; Porsteinsson 2001; Tariot
2005
Functional performance PSMS Porsteinsson 2001
Tariot 2005
Overall clinical impression CGI Porsteinsson 2001; Tariot 2001; Tariot 2005
Adverse effects Number of Adverse Reactions (checklist) Herrmann 2007; Porsteinsson 2001; Sival
2002; Tariot 2005
Coding Symbols for Thesaurus of Adverse Re-
action Terms (COSTART 1989)
Tariot 2001
BPRS: Brief Psychiatric Rating Scale; CMAI: Cohen-Mansfield Agitation Inventory; MMSE: Mini-Mental State Examination; PSMS:
Physical Self-Maintenance Scale.
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A P P E N D I C E S
Appendix 1. Sources searched and search strategies
Source Search strategy Hits
MEDLINE (OvidSP)








7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. (“organic brain disease” or “organic
brain syndrome”).mp
11. (“normal pressure hydrocephalus” and
“shunt*”).mp.
12. “benign senescent forgetfulness”.mp.
13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.










26. 20 and 25
27. randomised controlled trial.pt.








36. (animals not (humans and animals)).
sh.
37. 35 not 36
38. 26 and 37
39. (2008* or 2009* or 2010*).ed.
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(Continued)
Embase (OvidSP)








8. (lewy* adj2 bod*).mp.
9. deliri*.mp.
10. (chronic adj2 cerebrovascular).mp.
11. (“organic brain disease” or “organic
brain syndrome”).mp
12. “supranuclear palsy”.mp.
13. (“normal pressure hydrocephalus” and
“shunt*”).mp.
14. “benign senescent forgetfulness”.mp.
15. (cerebr* adj2 deteriorat*).mp.
16. (cerebral* adj2 insufficient*).mp.
17. (pick* adj2 disease).mp.











29. 23 and 28
30. randomised controlled trial/







38. 29 and 37
39. (2008* or 2009* or 2010*).em.





[Most recent search: 7 December 2017]
1. exp Dementia/
2. exp Delirium/
3. exp Huntingtons Disease/
4. exp Kluver Bucy Syndrome/
5. exp Wernickes Syndrome/
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9. (lewy* adj2 bod*).mp.
10. deliri*.mp.
11. (chronic adj2 cerebrovascular).mp.
12. (“organic brain disease” or “organic
brain syndrome”).mp
13. “supranuclear palsy”.mp.
14. (“normal pressure hydrocephalus” and
“shunt*”).mp.
15. “benign senescent forgetfulness”.mp.
16. (cerebr* adj2 deteriorat*).mp.
17. (cerebral* adj2 insufficient*).mp.
18. (pick* adj2 disease).mp.












30. 24 and 29
31. (2008* or 2009* or 2010*).up.
32. 30 and 31
CINAHL (EBSCOhost)
[Most recent search: 7 December 2017]
S1 (MH “Dementia+”)
S2 (MH “Delirium”) or (MH “Delir-
ium, Dementia, Amnestic, Cognitive Dis-
orders”)
S3 (MH “Wernicke’s Encephalopathy”)
S4 TX dement*
S5 TX alzheimer*
S6 TX lewy* N2 bod*
S7 TX deliri*
S8 TX chronic N2 cerebrovascular
S9 TX “organic brain disease” or “organic
brain syndrome”
S10 TX “normal pressure hydrocephalus”
and “shunt*”
S11 TX “benign senescent forgetfulness”
S12 TX cerebr* N2 deteriorat*
S13 TX cerebral* N2 insufficient*
S14 TX pick* N2 disease
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S19 S1 or S2 or S3 or S4 or S5 or S6 or S7
or S8 or S9 or S10 or S11 or S12 or S13 or
S14 or S15 or S16 or S17 or S18




S24 S20 or S21 or S22 or S23




S29 S26 or S27 or S28
S30 S25 and S29
Web of Knowledge (all databases)
[Most recent search: 7 December 2017]
Topic=(dement* OR alzheimer* OR AD
OR lewy) AND Topic=(valproic* OR val-
proate OR divalproex*) AND Topic=(ran-
dom* OR trial OR placebo OR “double







[Most recent search: 7 December 2017]
vaproate OR valpric$ OR divalproex$
[Words] and demenc$ OR dement$ OR





[Most recent search: 7 December 2017]





CENTRAL (the Cochrane Library)
[Most recent search: 7 December 2017]
#1 MeSH descriptor Dementia explode all
trees
#2 MeSH descriptor Delirium, this term
only
#3 MeSH descriptor Wernicke En-
cephalopathy, this term only
#4 MeSH descriptor Delirium, Dementia,
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(Continued)
brain syndrome”
#11 “normal pressure hydrocephalus” and
“shunt*”








#20 (#1 OR #2 OR #3 OR #4 OR #5 OR
#6 OR #7 OR #8 OR #9 OR #10 OR #
11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19)





#25 (#21 OR #22 OR #23 OR #24)
#26 (#20 AND #25), from 2008 to 2010
ClinicalTrials.gov
[Most recent search: 7 December 2017]
Interventional Studies | dementia OR
alzhiemer OR alzheimers OR alzheimer’s





ICTRP (The WHO portal)
[Most recent search: 7 December 2017]
Interventional Studies | dementia OR
alzhiemer OR alzheimers OR alzheimer’s
OR agitation | valproate OR valproic OR
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W H A T ’ S N E W
Last assessed as up-to-date: 7 December 2017.
Date Event Description
7 December 2017 New search has been performed A top-up search was performed for this review on 7
December 2017
7 December 2017 New citation required but conclusions have not
changed
No new studies added. Conclusions unchanged. Re-
view revised in line with MECIR standards. New au-
thors added
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 2, 2004
Date Event Description
4 November 2016 New search has been performed An updated search was performed for this review on
04 November 2016. No new studies were identified for
either inclusion or exclusion within the review
2 October 2014 New search has been performed An update search was performed for this review on 30
July 2010. No new studies were identified for either
inclusion or exclusion within the review
An update search was performed for this review on
02 October 2015. No new studies were identified for
either inclusion or exclusion within the review
31 October 2008 New search has been performed February 2008: A new update search for the review
was run. Some possible new studies for inclusion or
exclusion were retrieved
31 October 2008 New citation required but conclusions have not
changed
October 2008: Two new controlled studies were re-
viewed (Tariot, 2005; Herrman, 2007).These studies
were incorporated into a meta analysis that examined
the effect of valproate preparations on agitation as mea-
sured by the Cohen-Mansfield Agitation Index score
and by the Brief Psychiatric Rating Scale. In addi-
tion, meta analysis was uses to examine the frequency
of adverse events in valproate patients compared with
placebo treated patients
Both studies confirmed the Cochrane report of 2004
(Lonergan, 2004) that valproate preparations showed
no effect on agitation as compared with placebo con-
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(Continued)
trols. Further meta analysis also demonstrated among
valproate patients increased adverse events, especially
falls, infection, gastrointestinal disorders, and decreased
platelet counts compared with placebo treated patients
At this time valproate preparations cannot be recom-
mended for the control of agitation in demented pa-
tients)
12 August 2005 New search has been performed Minor update: 12 August 2005. In a new controlled
study of the effect of divalproex sodium on agitation
in demented patients, reported in abstract form, Tariot
and associates (Tariot 2004) were unable to demon-
strate any significant difference in agitation among
treated patients (target dose of divalproex, 750 mg per
day), compared with placebo controls. This study will
be reviewed in greater detail when the published article
becomes available
11 February 2004 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
SB: drafting of updated review; selection of recent trials; extraction of data; interpretation of data analyses; updated review 2018.
UN: drafting of updated review; selection of recent trials; extraction of data; interpretation of data analyses; updated review 2018.
JL: drafting of review versions; selection of trials; extraction of data; interpretation of data analyses; original review 2004, updated
review 2009, and updated review 2018.
AC: drafting of updated review; correspondence; selection of recent trials; extraction of data; interpretation of data analyses; updated
review 2018.
E Lonergan (previous review author): drafting of review versions; correspondence; selection of trials; extraction of data; entry of data;
interpretation of data analyses original review 2004 and updated review 2009.
Ann Ludvik: consumer editor.
This review was peer reviewed anonymously in April 2004.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In many of the studies that the searches identified, the reporting of baseline clinical evaluation was not always specific or detailed.
We took a pragmatic approach to avoid risking the loss of relevant evidence and included studies despite this information not being
explicitly reported.
If an included study was discontinued due to a high level of dropout and adverse effects experienced by the treatment group, we decided
that this presented a high risk of attrition bias and so excluded data from the pooled analysis from the outcome measures.
One of the aims stated in the protocol was to examine the effect of valproate preparations on carer burden. All of the included studies
were carried out in long-term care settings and not in the community; consequently, none of the studies attempted to assess carer
burden, and so analysis of such effects was not possible.
The original protocol proposed analysis treatment efficacy by type of dementia, degree of dementia, age, and sex if number of participants
was sufficient. The low number of included studies meant that the number of participants were not sufficient for such subgroup analysis.
The original protocol stated participants receiving more than one psychopharmacological agent at the time of the study would be
excluded from the report. In this 2018 updated review, we excluded participants receiving chronic therapy with other psychoactive
medications from the review except for those studies where treatment with an additional psychotropic medication was permitted in
the study protocol. Participants receiving treatment for dementia with cholinesterase inhibitors or memantine or receiving long-term
unchanged antidepressant treatment were not excluded from the review. Often clear information regarding concomitant medication
was not reported.
The original protocol proposed analysis of effect of treatment on one or more specific aspects of agitation. The low number of included
studies meant that the number of participants were not sufficient for such analysis.
The original protocol proposed analysis of effect of treatment of different forms of valproic acid (e.g. divalproex versus sodium valproate).
The number of included studies was too low to enable such analysis. It was also proposed to determine if the response to treatment was
influenced by the dose or duration of treatment. Four of the five included studies involved the same duration of treatment preventing
assessment of the impact of duration of treatment, and all studies varied in terms of the medication and dose used. The number of
studies included was too low to enable any analysis of these aspects of the treatment.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimanic Agents [adverse effects; ∗therapeutic use]; Dementia [∗complications]; Psychomotor Agitation [∗drug therapy; etiology];
Randomized Controlled Trials as Topic; Treatment Outcome; Valproic Acid [adverse effects; ∗therapeutic use]
MeSH check words
Aged; Humans
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